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I have established an efficient model of directing human embryonic stem cells 
(hESCs) to differentiate into the trophoblast lineage, the embryo’s cellular 
contribution to the placenta. This rapid and uniform differentiation process is 
induced by the combined treatment of a specific fibroblast growth factor receptor 
(FGFR) inhibitor and bone morphogenetic protein 4 (BMP4). Utilizing this model, I 
was able to probe the molecular mechanism driving hESCs towards the trophoblast 
lineage. This method provides a model to investigate the earliest stages of human 
development, an area still largely unexplored due to obvious ethical issues related to 
working with human embryos. In addition, the model, with its robust and uniform 
differentiation from the hESC, is unique in its utility to understand the molecular 
mechanisms involved in the loss of totipotency. This thesis will present studies of 
the onset of trophoblast differentiation, the stepwise molecular changes that occur 
during this differentiation process. This thesis will then present the commitment time 
point determination at which point the differentiated cells can no longer revert back 
to the hESC phenotype. Finally this thesis will discuss the specific roles of fibroblast 
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1.1 Introductory statement 
Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of the 
preimplantation embryo. ESCs are pluripotent stem cells as, under well established 
culture conditions, they have the ability to both remain undifferentiated by way of 
self-renewing cell division while still maintaining the ability to differentiate to 
almost all types of tissue. This ability to differentiate into all cell types is what drives 
the extensive clinical interest in human ESCs as there is great potential for use in 
medical applications such as cell-based therapies. For the medical use of ESCs, it is 
essential to understand the mechanisms involved in maintaining ESCs in their 
pluripotent, self-renewing state, and the mechanisms involved in their differentiation 
towards certain cell lineages. My thesis is focused on describing the earliest events 
of differentiation along the trophoblast lineage and blocking essential signals 
required for the maintenance of the undifferentiated hESC. As such, this introduction 
provides background on the culture conditions and the underlying molecular 
mechanism controlling the undifferentiated hESCs. I also include a review of the 
underlying molecular mechanism controlling the undifferentiated mouse ES cells to 
highlight the similarities and differences of ES cells between human and mouse. I 
will review the FGF and BMP signaling pathways as these are the two signaling 
pathways for manipulation in my study,. Also included are reviews on early events 
in human development, placentation, and the trophoblast lineage. 
 
   
 
3
1.2 The early embryo and placenta development 
Unlike a number of other mammalian species that are more amenable to 
experimentation, there is very little molecular data available on early human 
development. There is extensive knowledge of human preimplantation embryo 
morphology as morphological criteria are used clinically to choose embryos for 
transfer in assisted reproductive technologies (Urman et al., 2007). Any human 
cell-based model that is relevant to these developmental stages would have a great 
impact on the field of assisted reproductive biology allowing experimentation that 
does not depend on a limited supply of human embryos excess to reproductive 
technologies. The current understanding of human blastocyst biology and 
implantation is described below. 
1.2.1 Human preimplantation development: from zygote to implanting 
blastocyst  
Preimplantation development refers to the period of development from the point at 
which the egg is fertilized by the sperm up until the time when the embryo implants 
into the uterine wall of the mother. By definition this developmental program is 
restricted to the mammals (eutherians and metatherians) as non-mammalian 
vertebrates lay eggs after internal fertilization (birds, reptiles, and prototherian 
mammals) or begin development by the external fertilization of eggs (amphibians 
and fish). Human ovulation occurs in each menstrual cycle, whereby the human 
oocyte is delivered from the ovary into the fallopian tube. Within 48 hours of 
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ovulation, the human oocyte must be fertilized by the sperm in the fallopian tube 
whereupon it will begin to develop into a full organism. The newly fertilized zygote 
then passes through the fallopian tube towards the uterus. The developmental 
progression from the 1-celled zygote to the morula, when the embryo is a compacted 
ball of cells without a fluid-filled cavity, occurs in the fallopian tube. Two to three 
days after fertilization, the morula reaches the uterine cavity and subsequently 
develops into a blastocyst. 
The blastocyst is defined by its fluid-filled cavity, the blastocoel. The single outer 
layer of cells in the blastocyst, and the one responsible for cavity formation, is 
termed the trophectoderm (TE). The TE is the first epithelium that forms in 
mammalian development. The TE will subsequently give rise to all extraembryonic 
ectoderm/trophoblast cell types that contribute to the placenta. Although yet to be 
characterized in molecular detail in human, extrapolating from the mouse we know, 
the ICM within the blastocyst consists of two cell types: the epiblast and the 
primitive endoderm (PE). The epiblast, after implantation, will give rise to the three 
germ layers (definitive ectoderm, mesoderm, and endoderm) and to the germ cells 
themselves and thus to all cells in the whole fetus and to subsequent generations. The 
PE gives rise to all extraembryonic endoderm structures such as those found in the 
yolk sac. About 3 days after entering the uterus, the blastocyst hatches from the zona 
pellucida which is a non-adhesive and protective extracellular layer enclosing the 
embryo since fertilization. This hatching occurs much earlier in development than 
hatching in birds and other non-mammalian vertebrates and is the beginning of the 
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mammalian-specific developmental program of placental development. The placenta 
is the organ that establishes the nutrient supply from the mother, this as opposed to 
the yolk-based nutrient source found in the egg of non-mammalian vertebrates. 
Implantation requires major tissue remodeling of the endometrium from the initial 
point of embryo contact to the invasion of the maternal blood supply by the 
trophoblast-derived spiral arteries. At the same time, it is essential that signals are 
generated to communicate with the mother that a pregnancy is occurring otherwise 
the endometrial lining (along with the implanting embryo) will be sloughed off to 
initiate another menstrual cycle. Human implantation occurs approximately 8 days 
after fertilization. The implantation process has been classified into three steps: 
apposition, adhesion and invasion. Apposition is an unstable adhesion process that 
microvilli on the apical surface of multinucleate syncytiotrophoblasts start to 
interdigitate with pinopodes of the apical surface of the uterine epithelium (Wang 
and Dey, 2006). The syncytiotrophoblast layer is formed via cell fusion of 
cytotrophoblasts (CTB). More stable adhesion is achieved by increased physical 
interaction between the blastocyst and the uterine epithelium. Invasion occurs when 
syncytiotrophoblasts penetrate the uterine epithelium shortly after adhesion. 
Evidence suggests that fibronectin (FN) expressed on the surface of the blastocyst is 
involved in human blastocyst apposition. FN can be detected on the surface of the 
blastocyst but is not present on the morula. Fibronectin is a CD26 ligand and CD26 
was found to be expressed on the endometrial epithelium during the implantation 
period in women (Imai et al., 1992). Using a human cell line overexpressing CD26 
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as a model of the receptive endometrium Shimomura et al 2006 (Shimomura et al., 
2006) showed that there was a significantly higher human blastocyst adhesion rate 
and larger outgrowth area of the trophectoderm onto these CD26 cells than 
untransfected controls. In addition, L-selectin was found to mediate the embryo 
adhesion to the uterus. L-selectin is expressed by human trophoblasts on the fetal 
side and selectin oligosaccharide-based ligands is up-regulated by human uterine 
epithelial cells on the maternal side during the window of receptivity (Genbacev et 
al., 2003). The paucity of information in human for embryo-derived implantation 
molecules is in contrast to what is known from other mammals (Spencer et al., 2004; 
Wang and Dey, 2006). 
1.2.2 Early trophoblast morphology and function 
In humans, about 4 days after the initial implantation, the blastocyst is fully 
embedded in the stromal tissue of the uterus. Shortly after the blastocyst attaches and 
implants into the endometrium of the mother (no later than 9 days post-fertilization), 
a large population of cytotrophoblast expand from the trophectoderm of the 
blastocyst (Luckett, 1978). In humans, the trophoblast outgrowth consists of floating 
villi and anchoring villi.  
The floating villi are surrounded by maternal blood. From the floating villi, 
mononuclear cytotrophoblast stem cells fuse to form the multinucleated syncytium 
(syncytiotrophoblast), streaming out of the trophoblast layer to invade through the 
endometrium and reach the inner lining of the myometrium (Pijnenborg et al., 
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1981a), accompanied by endovascular invasion. The endovascular invasion 
establishes the uteroplacental circulation, placing trophoblasts in direct contact with 
maternal blood vessels and diverting the uterine blood flow to the placenta 
(Pijnenborg et al., 1981b). The syncytium functions to transport nutrients and O2 
from the maternal to the foetal circulation and transport the waste and CO2 in an 
opposite way. Additionally, the syncytium secretes critical placental hormones 
human chorionic gonadotropin (hCG) (Morrish et al., 1998; Muyan and Boime, 
1997), chorionic somatomammotropin hormone 1 (CSH1, also known as placental 
lactogen (PL)) (Handwerger and Freemark, 2000) and placental growth hormone 
(GH) (Lacroix et al., 2002). 
Oxygen tension determines the proliferation or differentiation of cytotrophoblasts. 
The human uterine surface at the time of implantation is a hypoxic environment with 
oxygen concentrations as low as 2%. In the early developing placenta (before 10 
weeks of gestation) oxygen tension remains low. The early human cytotrophoblast 
cells appear to remain undifferentiated and to be programmed to develop 
appropriately in this environment. An initial expansion/proliferation of this cell 
population will be induced by low oxygen as determined by in vitro studies 
(Genbacev et al., 1997). This hypoxia-induced explosion in the number of 
cytotrophoblasts presumably supplies adequate cell numbers to begin to establish the 
placenta. The nearer to the maternal arterioles oxygen tension increases eventually 
reaching 20%, this increased oxygen concentration induces the differentiation of 
cytotrophoblasts to an invasive phenotype, as evidenced from in vitro studies 
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(Genbacev et al., 1997), and subsequently establishes the intimate maternal-fetal 
interface.  
In the cell column of the anchoring villi, interstitial cytotrophoblasts (ICTB) 
proliferate and migrate into maternal deciduas and part of the myometrium. Some 
ICTB invade into spiral arteries to form endovascular cytotrophoblasts (ECTB) 
which replace the endothelium of maternal vessels (Pijnenborg et al., 1983).  
1.2.3 Key factors modulating early trophoblast development 
Several factors are essential for early placental development, such as hormones, 
growth factors, transcription factors and immune repression genes. Again, little of 
the molecular regulation of the human embryo is known and is extrapolated from the 
mouse and other mammals. 
1.2.3.1 Hormone related genes 
Before ovulation, the secretion of estradiol-17β is required for implantation because 
it stimulates the uterine epithelial cells to proliferate and differentiate in preparation 
for embryo implantation (Norwitz et al., 2001). During human placenta formation, 
estradiol-17β directly induces terminal differentiation of cytotrophoblasts 
(Yashwanth et al., 2006). HSD17B1 catalyzes estrone to estradiol, and HSD17B2 
catalyzes estradiol to estrone. Estrone, one form of estrogen, is secreted by the 
ovaries. HSD17B1 was detectable in human syncytiotrophoblast of 4 weeks 
gestation to term placenta, while HSD17B2 detectable in human endothelial cells of 
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intravillous vessels from 12 weeks gestation (Takeyama et al., 1998).   
HSD3B1 and CYP11A1/P450scc are the two enzymes required for steroid 
biosynthesis including progesterone synthesis. Human progesterone released from 
the corpus luteum stimulates the proliferation and differentiation of stromal cells of 
the uterus. The continued production of progesterone by the corpus luteum is 
required to keep the endometrial lining of the uterus intact to maintain pregnancy. 
After about seven to nine weeks of gestation the placenta then takes over this 
production of progesterone. If the lining of the uterus sheds off, the maturing embryo 
would no longer be anchored in the uterus resulting in a miscarriage (Csapo and 
Pulkkinen, 1978; Peyron et al., 1993). Thus it is essential to maintain a 
progesterone-producing corpus luteum immediately after implantation. The signal 
that communicates implantation/pregnancy to the corpus luteum is the 
trophoblast-derived human chorionic gonadotropin (hCG) (Keay et al., 2004). This 
endocrine action of hCG beginning at the earliest stages of embryo implantation is 
the reason why hCG is the molecule measured in pregnancy tests. hCG is composed 
of two subunits, CGA and CGB, both are expressed in the blastocyst though CGA 
appears to be the earliest detectable (Hay and Lopata, 1988). 
As an indicator of early pregnancy much interest has been focused on the regulation 
of hCG as understanding the transcription factors controlling its early expression 
would provide insight into the molecular regulation of early human development. In 
fact, CGA and CGB were the first described human targets of OCT4 (gene name 
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POU5F1), both are repressed by OCT4 (Liu et al., 1997; Liu and Roberts, 1996). As 
described in the mouse, Oct4 is a transcription factor that is essential for proper 
formation of the ICM and maintenance of the pluripotent cell (Nichols et al., 1998; 
Niwa et al., 2000); the likely scenario in early human development is hCG is only 
up-regulated in the trophectoderm once OCT4 has been turned off. hCG is positively 
regulated by multiple factors: the enhancer of CGA is bound by GATA2 and GATA3 
(Steger et al., 1994) and the promoter of CGA is bound by DLX3 (Roberson et al., 
2001), all these transcription factors are known trophoblast markers. The promoter 
region of the CGB5, one of many CGB paralogs, is bound and regulated by PPARG 
(Tarrade et al., 2001). Whilst the induction of both CGA and CGB requires TFAP2C 
in human trophoblast cells (LiCalsi et al., 2000; Steger et al., 1993). 
Relaxin (encoded by RLN1) plays a role in the mammalian reproductive system to 
ripen the cervix, elongate the pubic symphysis and inhibit uterine contraction. 
Relaxin is significantly increased with preterm rupture of the human fetal 
membranes (Tashima et al., 2002). One of its receptors LGR7 was found to be 
expressed in the human fetal membranes and placenta (Lowndes et al., 2006). With 
the presence of LGR7, human Relaxin enhances the promoter activity of Insulin-like 
Growth Factor Binding Protein-1 (IGFBP1) (Tang et al., 2005). 
The two human growth hormones (GH) are encoded by separate genes: GH1 (also 
called GH-N) encodes the pituitary growth hormone, whilst GH2 (also called GH-V) 
encodes the placental growth hormone. Placental GH gradually replaces the pituitary 
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GH during pregnancy. The placental GH is a trophoblast hormone that functions to 
allow the maternal metabolism to adapt to pregnancy, and exerts similar effects to 
that of pituitary GH (Caufriez et al., 1994; Fuglsang et al., 2003). TFAP2 was shown 
to bind to DNA sequences in the human GH1 promoter (Courtois et al., 1990; 
Imagawa et al., 1987). Placental GH was shown to regulate insulin-like growth 
factor 1 (IGF1) secretion during human pregnancy (Caufriez et al., 1994). 
In the human, the genes encoding for GH are structurally related to the genes 
encoding for placental lactogens (PL). PL is also an important pregnancy related 
hormone. PLs are encoded by three genes: CSH1 encodes for PL-A, CSH2 encodes 
for PL-B and CSHL1 encodes for PL-L (Richardson et al., 2000). The TFAP2 family 
can bind to the promoter of CSH1 (Richardson et al., 2000). PL functions along with 
GH2 in the mother to stimulate IGF1, enhancing the availability of glucose and 
amino acids to the fetus (Handwerger and Freemark, 2000; Whittaker et al., 1990). 
The enhancer elements of CSH2 were shown to be bound by TEAD3 during 
syncytium formation {Jacquemin, 1997 #601; Jacquemin, 1998 #602}. 
1.2.3.2 Growth factors 
Human placenta growth factor (PGF) was found to be expressed by trophoblast 
(Khaliq et al., 1996; Shore et al., 1997) and functions to promote extravillous 
trophoblast proliferation (Athanassiades and Lala, 1998).  
The heparin-binding epidermal growth factor (EGF) is involved in mouse embryo 
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implantation. When blastocysts are reactivated after artificially induced diapause, 
expression of heparin-binding EGF in the endometrium is up-regulated rapidly at the 
site of apposition of the blastocyst (Das et al., 1997; Das et al., 1994). Implanting 
blastocysts express EGF receptors and heparan sulfate proteoglycans (HSPG), both 
of which interact with EGF–like ligands. In addition to this unique physical role of a 
growth factor and its receptor in implantation it has also been shown that 
heparin-binding EGF can stimulate the proliferation and maturation of both mouse 
and human preimplantation embryos in vitro (Martin et al., 1998; Wang et al., 2000).  
Vascular endothelial growth factor (VEGF) is expressed in the human extravillous 
trophoblast, promoting angiogenesis and vascular hyperpermeability to stimulate 
proliferation of extravillous trophoblast (Athanassiades et al., 1998). 
Deletion of insulin-like growth factor 2 (Igf2) in mice resulted in a reduced growth 
of the placenta and fetal growth, due to decreased passive permeability of nutrients 
in the placenta (Constancia et al., 2002). In the human, IGF2 is abundantly expressed 
in the trophoblasts invading the walls of the maternal spiral arteries, with the greatest 
concentrations found at the invading front (Han et al., 1996). IGF2 was also shown 
to stimulate human extravillous trophoblast cell migration by signaling through IGF 
type 2 receptor but not through IGF type 1 receptor (McKinnon et al., 2001). IGF 
binding protein (IGFBP) binds to IGF to sustain the IGFs and alters their interaction 
with cell surface receptors. Human IGFBP3 mRNA is expressed in certain 
intermediate trophoblasts of the basal plate, the anchoring villi of placenta, the 
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mesodermal core, amnion and chorion (Han et al., 1996). As mentioned above, the 
promoter activity of IGFBP1 can be enhanced by relaxin (Tang et al., 2005); in the 
mother, the secretion of IGF1 has been reported to be stimulated by PL and GH2 to 
enhance the availability of glucose and amino acids to the fetus (Caufriez et al., 1994; 
Handwerger and Freemark, 2000; Whittaker et al., 1990). 
1.2.3.3 Transcription Factors 
Some transcription factors have been identified as key players in TE development 
and trophoblast stem cells (TS cells) establishment and maintenance.  
TEA domain family member 4 (TEAD4) is the earliest gene identified to date 
uniquely required for specification of the trophectoderm lineage. Mouse Tead4 null 
embryos are preimplantation lethal and do not express the trophectoderm 
(TE)-specific gene Cdx2 nor do they form any functional trophectoderm (Yagi et al., 
2007). Human TEAD3 was shown to increase during syncytium formation and 
interacts with enhancer elements of Csh2 which encodes placental lactogen B 
{Jacquemin, 1997 #601; Jacquemin, 1998 #602}.  
In mouse, the caudal-related homeobox gene (Cdx2) is strongly expressed in the 
outer cells at the late mouse morula stage; and its expression is restricted to the TE in 
the blastocyst stage, playing the role as one of the earliest transcription factors in TE 
development. Though the TE is still able to form in Cdx2 null embryos, the 
blastocyst is defective. The blastocoel of mutant embryos collapses and these 
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blastocysts fail to implant and thus do not develop beyond this stage. Some TE 
markers cannot be detected in the Cdx2 mutant embryos. However, pluripotency 
markers Oct4 and Nanog, normally restricted to expression within the ICM, can be 
detected in the TE cells of mutant embryos (Chawengsaksophak et al., 1997; 
Strumpf et al., 2005). This ectopic expression of Oct4 and Nanog in Cdx2 mutant 
embryos suggests Cdx2 is required for segregation of the ICM and TE lineages at the 
blastocyst stage, by repressing Pou5f1 and Nanog expression in the TE (Strumpf et 
al., 2005). The reciprocal inhibition between Cdx2 and Pou5f1 is believed to 
determine trophectoderm formation, because forced repression of Pou5f1 and 
overexpression of Cdx2 can both induce mESC differentiate towards trophectoderm 
(Niwa et al., 2005). 
Mouse embryos with a targeted deletion of the T-box gene Eomesodermin (Eomes) 
die soon after implantation. Although they are able to form blastocysts and implant, 
development is arrested shortly after implantation due to a failure to continue to 
proliferate and differentiate the trophoblast lineage (Russ et al., 2000; Strumpf et al., 
2005) In Eomes mutant blastocysts, Cdx2 and Oct4 are not affected as they are 
appropriately expressed, suggesting Cdx2 is upstream of Eomes (Strumpf et al., 
2005). Placental formation in Esrrb mutant mice was severely impaired with an 
overabundance of trophoblast giant cells in the early extra-embryonic ectoderm, 
suggesting trophoblast stem (TS) cells fail to maintain proliferation in the absence of 
Esrrb (Luo et al., 1997). Esrrb is not detected both in Cdx2 and Eomes mutants, 
suggesting that Esrrb is downstream of Cdx2 and Eomes (Strumpf et al., 2005). 
   
 
15
Inhibition of Esrrb by diethylstilbestrol also causes TS cells to differentiate 
(Tremblay et al., 2001), consistent with the above in vivo study.  
Mice with a deletion in the distal-less homeobox 3 (Dlx3) gene die between 
embryonic day 9.5 and day 10 because of placental failure with defects in the 
labyrinthine layer (Morasso et al., 1999). DLX3 was shown to be expressed in 
human placental cells (Holland et al., 2004) and it directly activates the gene 
encoding the α subunit of hCG hormone (CGA) (Roberson et al., 2001). Dlx3 is 
shown to be regulated by BMP signaling because it responds negatively to BMP 
antagonists chordin or the truncated BMP receptor (Suzuki et al., 1994). In human 
trophoblast cells, the binding of DLX3 to a downstream target was found to be 
inhibited by SMAD6, an inhibitory Smad (Berghorn et al., 2006). Dlx5 was also 
shown to be the target of BMP signaling in mouse (Miyama et al., 1999). 
Members of the transcription factor AP-2 family, TFAP2 (Tcfap2 in mouse) have 
also been identified to have a role in the trophoblast lineage. Mouse embryos null for 
Tcfap2c die at E7.5 with extra-embryonic tissue malformations and a failure to form 
the maternal-fetal interface (Auman et al., 2002). Redundancies in the Tcfap2 family 
may mask an even earlier role of Tcfap2a in the mouse trophoblast lineage (Winger 
et al., 2006) as a number of family members are expressed in implanting blastocyst 
and are restricted to the trophectoderm. In the human TFAP2A is critical for 
trophoblast differentiation and maturation (Cheng et al., 2004) and TFAP2C was 
shown to be required for the induction of both subunits of hCG, CGA and CGB 
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(LiCalsi et al., 2000; Steger et al., 1993). TFAP2 family members were also shown 
to bind to the CSH1 promoter (Richardson et al., 2000) and to the GH1 promoter in 
human (Courtois et al., 1990; Imagawa et al., 1987). 
GATA binding protein 2 (Gata2) and Gata3 are expressed in mouse trophoblast giant 
cells (Ng et al., 1994) and unpublished data from our lab clearly show both are 
expressed in the mouse blastocyst, are specific to the trophectoderm, and Gata3 is 
capable of driving trophoblast gene expression when over-expressed in mouse ES 
cells. Mouse placentas lacking either Gata2 or Gata3 show reduced expression of 
placental hormone lactogen I and the angiogenic hormone proliferin (Ma et al., 
1997). In addition, human GATA2 and GATA3 have been implicated in the 
regulation of hCG α-subunit CGA in placenta (Steger et al., 1994). Thus both these 
closely related homologs are expressed in the mammalian placenta and have been 
implicated in the regulation of a number of placental hormones. Similar to TFAP2 
family members, functional redundancy in Gata2/3 may mask an earlier essential 
function of these transcription factors.  
Inhibitor-of-DNA-binding (ID) proteins are basic helix-loop-helix (bHLH) proteins 
that lack the DNA binding domain found in bHLH transcription factors. As such, the 
inhibitory function of ID proteins comes from their ability to dimerize with bHLH 
transcription factors and block their binding to DNA. ID2 is expressed in human 
trophoblast progenitor villous cytotrophoblasts (Janatpour et al., 1999). Its functional 
role is to prevent bHLH factors from dimerizing, binding DNA and trans-activating 
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lineage-specific genes (Janatpour et al., 2000). In addition, ID2 is highly specific for 
the trophectoderm in the mouse blastocyst (unpublished data from our group). Id1 
was also shown to be involved in rat trophoblast gene regulation (Takeda et al., 
2007). As a bHLH transcription factor expressed in the trophoblast, heart and neural 
crest derivatives expressed 1 (HAND1) is a potential target of ID proteins. In mouse 
HAND1 is required for the differentiation of primary and secondary giant cells 
(Firulli et al., 1998; Riley et al., 1998; Scott et al., 2000). In the human, HAND1 has 
been detected in the trophectoderm of the blastocyst (Knofler et al., 2002). Though 
direct biological targets of HAND1 have yet to be characterized, it has been shown 
to be able to both activate and repress transcription from luciferase reporter 
constructs (Knofler et al., 2002). 
Transcription factor glial-cells-missing-1 (GCM1) was found constitutively 
expressed in human placental cytotrophoblasts (Janatpour et al., 1999). Mouse Gcm1 
is expressed in chorionic trophoblast cells. Mice lacking Gcm1 die at E10 because of 
a block in the branching of the chorioallantoic interface and an absence of the 
placental labyrinth (Anson-Cartwright et al., 2000). Several potential binding sites 
for GATA transcription factors were found in the 5’-flanking region of human 
GCM1, suggesting GCM1 is the potential target of GATA genes (Yamada et al., 
2000). GCM1 was found to regulate the expression of CYP19A1, a gene that is 
strongly induced in human syncytium formation (Jiang et al., 2000) and encodes for 
aromatase which catalyzes the last steps of estrogen biosynthesis (Nait-Oumesmar et 
al., 2000; Yamada et al., 1999). GCM1 was also found to regulate the expression of 
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syncytin (Yu et al., 2002a). Syncytin, an endogenous retroviral envelope protein 
encoded by ERVWE1, is specifically expressed in the syncytiotrophoblast layer. 
Syncytin was shown to be directly involved in mediating the fusion of 
cytotrophoblasts into the syncytiotrophoblast layer (Frendo et al., 2003). GCM1 was 
also found to regulate Placental Growth Factor (PGF) in the human trophoblast 
(Chang et al., 2008). 
1.2.3.4 Immune related factors in placenta 
1.2.3.4.1 Immunosuppression in placenta 
The mother and the fetus share only half of their genetic constituents, thus without 
specific intervention the mother should generate graft-attacking antibodies and 
cytotoxic T lymphocytes (CTL) to foreign antigens expressed by the baby. And, 
indeed this occasionally occurs, particularly in Rhesus D Hemolytic disease of the 
newborn, where a blood incompatibility can result in immune rejection of the 
developing baby, causing a variety of effects on the newborn. It is unclear exactly 
how this semi-allograft avoids the mother’s immune system but there is evidence 
that the invading trophoblast cells from the implanting blastocyst, which are in direct 
contact with the maternal immune system from the implanting blastocyst express 
molecules to aid in immune suppression. Placental cells have the capacity to 
selectively express specific genes of the human leukocyte antigen (HLA). HLA, 
name of major histocompatibility complex (MHC) in humans, is the strongest 
stimulator of graft rejection. HLA consists of two sub-groups: class I and class II, 
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only the class I HLA are expressed in placenta. Class I HLA is subdivided into class 
Ia, which includes HLA-A, -B, and –C; and class Ib, which includes HLA-E, -F, and 
–G. Class Ia molecules of HLA are much more polymorphic than Class Ib 
(Bainbridge et al., 1999). Although classified into class Ia, HLA-C is moderately 
polymorphic. The polymorphic HLA-A and HLA-B molecules, which initiate 
allograft rejection, are not expressed in human trophoblasts; however, the less 
polymorphic HLA-C, HLA-E, HLA-F and HLA-G are expressed in human 
trophoblasts (Hunt et al., 2005; Kovats et al., 1990). HLA-G is believed to protect 
fetal tissues from the maternal immune system (Carosella et al., 2008a; Carosella et 
al., 2008b). Trophoblast cells are also able to avoid maternal natural killer cell 
monitoring and attacking independent of HLA class I expression (Avril et al., 1999).  
Additionally, the immunological tolerance is probably provided by the decidual 
leukocyte populations. The most abundant hematopoietic cell type of the decidua is 
uterine natural killer lymphocytes (uNKs) (65%–70%) in both humans and mice.  
About 10%–20% of the decidual leukocyte population is antigen-presenting cells 
(APCs) with the antigen-class II MHC molecule complex on the membrane, 
including B cells, macrophages and dendritic cells. In humans, B cells are virtually 
absent and T cells which recognize and interact with the APCs are sparse (Kammerer, 
2005) although T cells have been shown to be required for repressing maternal 
immune response in mouse (Heikkinen et al., 2004). CD11chi dendritic cells (DCs), 
representing around 5%–10% of all hematopoietic uterine cells (Blois et al., 2004),  
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were shown to be the most potent APC to induce the primary immune responses and 
also the immunological tolerance (Steinman et al., 2003).  
1.2.3.4.2 Non-immune function of immune cells 
In mice, depletion of uterine dendritic cells (uDCs) resulted in embryo resorption 
due to a severe impairment of decidual proliferation and differentiation in the 
implantation process. Surprisingly, this requirement of uDCs in the implantation 
process appear to be independent of their predicted role in immunological tolerance, 
but uDCs were shown to required for promoting decidual blood vessel maturation by 
providing sFlt1 and TGF-β1 (Plaks et al., 2008). 
Human CD56bright NK precursor cells are recruited from secondary lymphoid 
tissues and are activated in the maternal decidua during pregnancy. They are found in 
direct contact with fetal trophoblasts and have been shown to be important in 
trophoblast migration and decidual spiral artery transformation (Ashkar et al., 2000; 
Croy et al., 2003; Hanna et al., 2006). However, the NK cells are dispensable for 
mouse embryo implantation as the depletion of NK cells in mouse uterus during 
pregnancy was compensated by unknown mechanisms (Ashkar et al., 2000; 
Guimond et al., 1997). 
 
1.2.3.5 Other placenta related factors 
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Leukemia inhibiting factor (LIF) is an essential molecule in mouse implantation and 
its expression pattern in the human suggest it may also play a role in human 
endometrial receptivity. LIF levels rise greatly in the epithelium of the uterus in the 
midsecretory phase of the human menstrual cycle (Cullinan et al., 1996) and LIF 
secretion is much lower in the infertile women with recurrent implantation failure 
than normal women (Chaouat et al., 1995). LIF is required for decidualization and 
implantation in mouse (Stewart et al., 1992) and it is expressed by stromal cells 
surrounding the active blastocyst during mouse embryo implantation (Song et al., 
2000). 
In mouse, the BMP antagonist Noggin is expressed in the uterine stroma during the 
receptive phase. After blastocyst attachment, Bmp2 is induced in the stroma and 
followed by down-regulation of Noggin. Local delivery of Bmp2 or Bmp4 in the 
uterus causes aberrant embryo spacing of implantation sites (Paria et al., 2001). 
BMP4 has been reported to induce hESC (WiCell, H1, H7, H9 & H14) 
differentiation into trophoblast cell lineage (Xu et al., 2002b) though a second study 
indicated BMP induced hESC (ESI HES2 & HES3) differentiation along the 
extraembryonic endoderm lineage (Pera et al 2004). 
The ATP-binding cassette efflux transporter BCRP (gene symbol ABCG2) is 
abundantly expressed in the apical membrane of human placental 
syncytiotrophoblasts (Allikmets et al., 1998; Maliepaard et al., 2001), indicating that 
BCRP may function in expelling the potential toxic drugs, xenobiotics, and 
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metabolites across the placental barrier to protect the fetus (Mao, 2008). 
1.2.4 Clinical relevance of placenta development 
Human reproduction is a highly complex process which still remains largely 
unexplored at the molecular level. For women utilizing assisted reproductive 
technologies (ART) such as in vitro fertilization, the preimplantation embryos that 
are selected to be transferred to a woman’s uterus are largely chosen based on 
morphological criteria. The chance of successful birth from transferred embryos is 
approximately 34%. The chance of successful birth for all patients who resort to 
assisted reproductive technology is approximately 27.7%, lower because, for some 
patients, derivation of embryos of sufficient quality for transfer is unsuccessful 
(Assisted Reproductive Technology Report of US for the year 2004). In normal 
women, when sensitive methods of hCG detection are employed, 75% of pregnancy 
loss has been determined to be a result of failure of implantation, though such 
pregnancy failures are not clinically recognized as pregnancies (Wilcox et al., 1988). 
Though this measured failure would include embryos that arrest prior to and 
therefore not a result of implantation failure per se, this does not make the biological 
understanding of embryo implantation any less important. Thus a better 
understanding of the molecular mechanisms underlying implantation and 
placentation will be immediately impactful in the field of ART and later clinical 
complications related to the pregnancy.  
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1.3 Embryonic stem cells  
1.3.1 Mouse embryonic stem cells 
1.3.1.1 Derivation of mESC 
mESCs were first derived in 1981 {Martin, 1981 #292; Evans, 1981 #293}. mESCs 
are pluripotent cells derived from the ICM preimplantation embryos 3.5 to 4.5 days 
after fertilization. mESC have the ability to differentiate to all cell types of the fetus 
including the ectoderm, mesoderm, endoderm and germ cells as shown in chimeras 
and similar to their in vivo equivalent cells of the ICM (Beddington and Robertson, 
1989; Nagy et al., 1993). mESCs do not spontaneously differentiate to 
trophectoderm; to date this has only been achieved by genetic manipulation. Genetic 
manipulation resulting in decreased Pou5f1 induces mESCs differentiation to 
trophectoderm (Niwa et al., 2000), and similarly Parp1-deficienct mESC 
differentiate to the cells of the trophoblast lineage (Hemberger et al., 2003). 
However, wild type mESC injected back into the cavity of the blastocyst do not 
spontaneously give rise to TE nor to the primitive endoderm (Beddington and 
Robertson, 1989) which strongly indicates they are restricted in their developmental 
potential to the definitive lineages and germ cells. 
Recently, pluripotent epiblast stem cells (EpiSC) were derived from late epiblast of 
mouse embryos, at a stage after embryo implantation referred to as the egg cylinder 
stage. Like hESCs, and unlike mESCs which require LIF, the mouse EpiSCs were 
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cultured in medium supplemented with activin (20ng/ml) and FGF2 (12ng/ml) 
(Brons et al., 2007) or FGF2 alone 5ng/ml (Tesar et al., 2007). Intriguingly, these 
two reports indicate that mouse EpiSCs have a greater molecular similarity to hESC 
than they do to mESCs. In addition, they appear to share with hESC the ability to 
differentiate to the trophoblast lineage when induced by BMP4, which despite the 
fact that the in vivo mouse egg cylinder epiblast does not give rise to the trophoblast 
lineage. 
1.3.1.2 Culture condition of mESC 
mESC can be maintained in an undifferentiated state by culturing on feeders such as 
mouse embryonic fibroblast (MEF) or feeder-free in the presence of LIF (Gearing et 
al., 1987; Smith et al., 1988; Williams et al., 1988). LIF receptor gp130 is required to 
maintain the epiblast and the embryos ability to generate ES cells in embryos 
undergoing diapause (Nichols et al., 2001). 
1.3.1.3 Core signaling pathway of mESC 
1.3.1.3.1 LIF/STAT3 
mESCs can be maintained in the pluripotent state under feeder-free conditions in the 
presence of LIF. The signaling pathway triggered by extracellular LIF is transduced 
through phosphorylation of the cytoplasmic tail of the gp130/LIFR plasma 
membrane receptor upon binding of LIF. This sets off the JAK/STAT cascade that 
ultimately results in the signal transducers and activator of transcription 3 (STAT3) 
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entering the nucleus (Boeuf et al., 1997; Burdon et al., 1999a; Matsuda et al., 1999; 
Niwa et al., 1998) and presumably activating target genes (Chen et al., 2008b). 
1.3.1.3.2 Transcription factors 
Four transcription factors, Pou5f1, Sox2, Myc and Klf4, were shown to be able to 
induce mouse fibroblasts to the pluripotent state (Takahashi and Yamanaka, 2006). 
The transcription factor Pou5f1 (aka. Oct4) is expressed in mouse oocytes and in the 
preimplantation embryo. At the blastocyst stage, Pou5f1 expression eventually 
becomes restricted to the ICM of the blastocyst (Palmieri et al., 1994). Pouf5f1 
deficient mouse embryos fail to develop beyond the blastocyst stage due to defects 
in the ICM including the expansion of the expression into the ICM of the normally 
TE-restricted Cdx2 (Nichols et al., 1998). mESCs also strongly expressed Pou5f1 
and when this gene is conditionally inactivated mESC lose their pluripotency and 
differentiate along the trophoblast lineage and are capable of giving rise to TS cells 
(Niwa et al., 2000).  
The ICM of mouse embryos and mESCs also strongly express the homeodomain 
transcription factor Nanog. Nanog null mice fail to maintain a proper ICM with all 
cells apparently reverting to primitive endoderm resulting in early post-implantation 
lethality (Mitsui et al., 2003). mESCs lacking Nanog lose their pluripotency and 
differentiate towards extraembryonic endoderm and mesoderm lineages (Chambers 
et al., 2003; Mitsui et al., 2003). Nanog expression is up-regulated by binding of 
STAT3 to the 5' promoter region of Nanog, suggesting an interaction of Nanog and 
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LIF in maintaining mESC pluripotency (Suzuki et al., 2006). Pou5f1 and Sox2 were 
shown to bind to the Nanog promoter in vitro and in vivo in mouse and in hESCs 
(Rodda et al., 2005), and the oct/sox motif (octamer: TTTTGCAT, sox: TACAATG) 
is required for the activity of the Nanog promoter in mESC and hESC (Kuroda et al., 
2005). However, Nanog mRNA can be detected in POU5F1 deficient mice 
(Chambers et al., 2003), suggesting that Nanog can be expressed without POU5F1. 
FoxD3 is a forkhead family transcription factor; it is also highly expressed in mouse 
ES cells and in pluripotent cells of the early embryo (Sutton et al., 1996). FoxD3 null 
mouse embryos fail to form the epiblast in the post-implantation egg cylinder (E5.5) 
and die shortly after implantation (Hanna et al., 2002). FoxD3 was shown to activate 
Nanog by binding directly to the Nanog promoter (Avery et al., 2006). Tcf3 is a 
transcription factor downstream of the WNT pathway. Tcf3 is highly expressed in 
undifferentiated mESCs and it was shown to bind to the Nanog promoter and repress 
the promoter activity in mESC (Pereira et al., 2006). p53 may also negatively 
regulate Nanog by binding to Nanog promoter and p53 was induced and 
phosphorylated when Nanog expression was reduced in mESC differentiation (Lin et 
al., 2005). Zic3 is another transcriptional regulator of ESC pluripotency (Lim et al., 
2007) and Zic3 null embryos fail to form visceral endoderm (Ware et al., 2006). 
Sall4 is also a transcriptional regulator of ESC pluripotency (Zhang et al., 2006a) 
and Sall4 knocked out mice fail to form primitive endoderm (Elling et al., 2006; 
Sakaki-Yumoto et al., 2006).  
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1.3.1.4 Mouse trophoblast stem cells 
Mouse trophoblast cells have not been derived from mESC, however, mouse 
trophoblast stem (TS) cell lines can be derived from the blastocysts. Mouse TS cells 
can be maintained in the presence of FGF4 and fibroblast-conditioned medium 
(Tanaka et al., 1998) or activin and transforming growth factor (TGF)-β (Erlebacher 
et al., 2004). The interaction between the FGF and TGF pathways within the in vitro 
mouse TS cell remained unclear while in vivo, studies show that FGF4 and the 
TGF-β-related protein Nodal synergize to maintain a trophoblast stem cell 
microenvironment (Guzman-Ayala et al., 2004). When FGF4 is absent from the 
mouse TS cell medium and the O2 level is low (3%), trophoblast stem cells tend to 
differentiate into spongiotrophoblasts rather than giant cells (Adelman et al., 2000). 
mESC do not spontaneously differentiate into trophoblast lineage unless under 
genetic manipulation, like POU5F1 RNAi knock down (Velkey and O'Shea, 2003) 
or Parp1 knocked out (Hemberger et al., 2003). 
1.3.2 Human embryonic stem cell (hESC) 
1.3.2.1 hESC derivation 
The first hESC lines were successfully derived from in vitro fertilized embryos in 
1998 (Thomson et al., 1998). These were derived from immunosurgically isolated 
ICM of the 4 to 8 day blastocysts. hESC is the most exciting field of ESC study 
because it provides the potential for regenerative medicine in humans. hESC also 
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provides us the opportunity to study the early development of human embryos. They 
express typical ESC markers, such as POU5F1 and NANOG, possess high levels of 
telomerase activity and show normal karyotype. They can be maintained in an 
undifferentiated state by culturing on MEF cells, in MEF-conditioned media or in 
chemically defined medium (CDM). Most current hESC culture systems require the 
addition of exogenous FGF2. The role of FGF2 in maintaining hESC pluripotency 
may act through the mitogen-activated protein kinase (MAPK) (Kang et al., 2005). 
In contrast to hESC, the FGF signaling pathway induces differentiation in mESC 
(Burdon et al., 1999b).  
Like mESCs, hESCs have the potential to differentiate into numerous cell types of 
all three germ layers (ectoderm, mesoderm and endoderm) in vitro and in teratomas 
formed in living mice. However, unlike mESCs, hESCs can spontaneously 
differentiate to the trophoblast lineage. The comparison of mouse and human ESC is 
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Characteristic mESC hESC 
Markers of 
pluripotency 
Oct4, Rex1, Nanog, 
SSEA1,alkaline 
phosphatase  
Oct4, Rex1, Nanog, SSEA3, 
SSEA4 TRA-1-60, TRA-1-81, 
alkaline phosphatase  
In vitro spontaneous 
differentiation 
ectoderm, mesoderm and 
endoderm; trophectoderm 
(by gene manipulation) 
ectoderm, mesoderm, endoderm 
and trophectoderm 
Germline 
transmission? Yes N/A 
Derivation  
No immunosurgery 
required, trypsin can be 
used for the first passage 
Immunosurgery or microsurgery, 
or separation of the inner cell 
mass from the trophoblast at the 
earliest stages of outgrowth is 
required to prevent 
inner-cell-mass differentiation; 
propagation by mechanical 
dispersion is usually needed for 
several initial passages before 
the cells can be adapted to 
trypsin or collagenase 
Transfection  
Easy (can use conventional 
approaches) Difficult (lentivirus required)  
Feeder dependency 
on mEF or grow on gelatin 
with LIF presence 
on mEF with FGF2 or grow on 
Matrigel with CM 
Defined culture 
condition Yes Yes 
Karyotype stability 
Aneuploidy can be acquired 
in culture and is permissible 
for successful germline 
transmission if 50–100% of 
cells have normal karyotype 
Stability of karyotype through 
multiple passages is standard; 
acquired aneuploidy in 
chromosomes 12 and 14 has 
been reported for different lines 
that were passaged 
enzymatically  
Passaging techniques Trypsin 
Mechanical dispersion, trypsin, 
collagenase, dispase 
Passage period 2 days 7 days 
Essential cytokine LIF FGF2 
ERK activity 
Low in undifferentiated 
mESC, High in differentiated 
mESC, When inhibited, can 
improve mESC pluripotency  
high in undifferentiated hESC, 
low in differentiated hESC, 
When inhibited, hESC 
differentiate 
Characteristic mESC hESC 




Required for ESC 
self-renewal (Sato et al., 
2004) 
Required for ESC self-renewal 
(Sato et al., 2004) 
GDF3 
Reduced GDF3 support 
pluripotency 
Over expressed GDF3 support 
pluripotency 
TGF-β 
Smad2/3 is not required to 
maintain pluripotency. 
Smad2/3 is required to maintain 
pluripotency. 
BMP signaling 
low concentration help to 
maintain pluripotency  
induce differentiation towards 
trophoblast 
Table 1.1 Comparison between mouse and human ESCs, modified from(Klimanskaya 
et al., 2008). 
1.3.2.2 hESC culture condition  
The cytokine Leukemia Inhibitor Factor (LIF) alone is able to maintain mESCs. 
LIFR and gp130 are also expressed in hESCs and phosphorylation and translocation 
of STAT3 can be induced by human LIF but nuclear localization of STAT3 does not 
appear to be necessary for the maintenance of hESC (Daheron et al., 2004). LIF by 
itself is insufficient for hESC propagation and maintenance of pluripotency 
(Thomson et al., 1998).  
Abundant evidence shows that FGF is essential for maintaining hESC pluripotency, 
but the mechanism of FGF in hESC is still unclear.  
Traditionally and still commonly nowadays, hESCs can be cultured directly on a 
feeder layer or in feeder-free conditions. In both culture systems, feeder cells are 
required to generate unknown factors to support hESCs to maintain pluripotency. In 
feeder-free culture, hESC media is first used to culture feeder cells to obtain 
conditioned media (CM), and then the CM is supplemented with an additional FGF2 
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(4-8ng/ml) before used for hESC culture. It has been recently reported that FGF4 
(50ng/ml) is also able to maintain hESC self-renewal (Mayshar et al., 2008). 
Commonly, mitotically inactivated MEFs are used as feeder cells (Xu et al., 2001). 
Though xenobiotic concerns from human cells cultured on mouse feeder layers has 
led to the development of some human feeder cell lines  (Amit et al., 2003; Hovatta 
et al., 2003; Richards et al., 2002; Richards et al., 2003), with this there still remains 
the need for feeder cells to provide some unknown factors. One goal of hESC 
biologists has been an effort to establish fully defined culture conditions.  
To date, there have been several reports on how to maintain human ESCs in an 
undifferentiated condition without any form of feeders. In culture conditions 
containing both serum replacement and Matrigel, high levels of FGF2 (100ng/ml) 
alone (Levenstein et al., 2006; Xu et al., 2005a) or the BMP antagonist NOGGIN 
(500 ng/ml) combined with reduced levels of FGF2 (40 ng/ml) (Wang et al., 2005; 
Xu et al., 2005b) are sufficient to maintain the pluripotency of hESC without any 
contributions from feeder cells. Another report showed that activin A alone (5 ng/ml) 
was also sufficient to maintain undifferentiated hESCs without either feeder cells or 
conditioned medium (Xiao et al., 2006). Activin/Nodal and FGF2 (10 ng/ml 
Activin+ 12 ng/ml FGF2 or 100 ng/ml Nodal + 12 ng/ml FGF2) can cooperate to 
maintain pluripotency of hESCs in a chemically defined medium without serum 
replacement or Matrigel but with a fetal bovine serum (FBS) coating (Vallier et al., 
2005). Serum replacement media itself is not fully defined so some attempts to move 
away from this to fully chemically defined media (CDM) have been reported to 
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support self-renewal of hESCs grown on Matrigel-coated plates over multiple 
passages (Liu et al., 2006; Yao et al., 2006), though Matrigel too, is not fully defined. 
As any future hESC clinical applications would require a fully defined media 
including any reagent used passing good manufacturing practice (GMP) some effort 
has been put towards achieving this (Li et al., 2005; Lu et al., 2006; Ludwig et al., 
2006) culminating in the derivation and characterization of hESC lines under fully 
clinical GMP grade conditions (Crook et al., 2007).  
The huge clinical potential for hESC cell-based therapies lies in the hESCs ability to 
give rise to tissues representatives of all three embryonic germ layers. Based on 
morphological and histochemical analysis, numerous cell lineages, such as neuronal, 
cardiac, bone, squamous epithelium, skeletal muscle, gut and respiratory epithelia 
have been identified within hESC-derived teratomas. In addition, many cell types 
have been identified with in vitro differentiation of hESCs. Achieving directed 
differentiation to a single cell type will involve a defined multi-step differentiation 
process similar to that which occurs in vivo. This will likely involve the addition of 
particular growth factors and cytokines (or combinations there of) through different 
stages of the hESC differentiation process. 
1.3.2.3 Core signaling pathways of hESC 
Despite substantial differences in the overall transcriptomes between mouse and 
human ES cells (Wei et al., 2005), there has been no great difference yet identified in 
the underlying transcriptional network. In fact, all the main players initially 
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characterized in the mouse system are also functionally important in hESC. 
OCT4/POU5F1 is highly expressed in hESCs (Reubinoff et al., 2000; Xu et al., 2001) 
and is down-regulated upon differentiation, and is required to maintain hESC 
pluripotency (Lebkowski et al., 2001). NANOG and SOX2 are also highly expressed 
in hESCs, and are down-regulated when hESCs differentiate and the over-expression 
of NANOG enables feeder-free culture of hESCs (Darr et al., 2006). As described in 
the previous mESC review, POU5F1 and SOX2 were shown to bind to the NANOG 
promoter in vitro and in vivo in mouse and in hESCs (Rodda et al., 2005) and 
genome-wide chromatin immunoprecipitation (ChIP) DNA microarray studies, the 
so called ChIP-chip approach, have uncovered the DNA regions bound by POU5F1, 
NANOG and SOX2 in hESCs (Boyer et al., 2005). These three transcription factors 
show a high frequency of co-occupancy within the same gene regions and they also 
bind to their own promoters (Boyer et al., 2005). The importance of these three 
factors, in addition to MYC, KLF4, and LIN28, in achieving the human pluripotent 
cell state have been also shown through their role in generating human induced 
pluripotent stem (iPS) cells (Takahashi et al., 2007; Yu et al., 2007). 
1.3.2.4 hESC-derived trophoblast cells 
The ability of hESC to contribute to the trophoblast lineage was apparent from the 
first description of these cells (Thomson et al., 1998) as chorionic gonadotropin 
(hCG) was detected as secreted into the media of a 2 week spontaneous 
differentiation culture. Since then a number of methods have successfully been used 
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to drive hESCs along the trophoblast lineage. Embryoid bodies (EBs) of both 
suspension and adhesion culture generate some trophoblast cells (Gerami-Naini et al., 
2004). Harun et al (Harun et al., 2006) used rounds of cellular aggregation and 
disaggregation of human EBs to select for trophoblast enrichment and reported the 
derivation of cytotrophoblast stem cell lines from this. In addition and similar to 
mESC, hESC with POU5F1 knocked down by RNAi begin to express trophoblast 
markers (Babaie et al., 2006). 
hESCs have also been induced to differentiate into the trophoblast lineage by BMP4 
treatment (Xu et al., 2002b); however, another study showed that most BMP2/4/7 
treated hESCs differentiated towards extra-embryonic endoderm and only a small 
fraction of cells differentiate towards the trophoblast lineage (Pera et al., 2004). 
Blocking of BMP signaling by its inhibitor NOGGIN showed different effects by 
independent groups: some showed that NOGGIN cooperated with FGF2 to maintain 
hESC pluripotency (Wang et al., 2005; Xu et al., 2005b) while others showed 
enhanced neuronal differentiation (Pera et al., 2004; Sonntag et al., 2007). 
Nonetheless, this is in striking contrast to mESCs where BMP4 treatment aids in the 
maintenance of pluripotency (Ying et al., 2003a). 
BMP4-induced trophoblast differentiation is further supported in studies on 
phosphatidyl-inositol-glycan class A (PIGA) and 
glycosyl-phosphatidyl-inositol-anchored proteins (GPI-APs, which require PIGA for 
synthesis) where their defects result in a lack of GPI-anchored BMP co-receptors 
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(Chen et al., 2008a), thereby inactivating BMP signaling. hESCs with such defects in 
PIGA and GPI-APs, fail to form trophoblasts when induced to differentiate, whether 
by EB formation or by adding exogenous BMP4. 
1.4 FGF and TGF-β Signaling pathway 
1.4.1 Fibroblast growth factor (FGF) signaling 
Since the first FGF was discovered in 1974 (Gospodarowicz, 1974), 22 distinct 
members of the FGF family have been subsequently described. FGF family members 
range from 16 to 34 kilo Dalton (kDa) and share 13-71% amino acid identity. Across 
vertebrate species, FGFs are highly conserved in both gene structure and amino-acid 
sequence. FGFs have a high affinity for heparan sulfate proteoglycans and require 
heparan sulfate to activate the high-affinity transmembrane tyrosine kinase receptors 
(Ornitz, 2000). There are 5 FGF receptors (FGFRs) in mouse and human. Among 
them, FGFR1, FGFR2, FGFR3 and FGFR4 share a similar structure: they consist of 
a hydrophobic leader sequence, two or three immunoglobulin-like domains, a 
heparin binding sequence, an acidic box, a short transmembrane region, and two 
tyrosine kinase domains (Johnson et al., 1990; Lee et al., 1989; McKeehan et al., 
1998). FGFR5 was reported to contain no intracellular kinase domain and its 
function is largely unknown (Kim et al., 2001; Sleeman et al., 2001). 
1.4.1.1 Signaling cascade  
FGFR conformational changes upon binding of FGF lead to receptor dimerization 
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and tyrosine kinase activation, leading to autophosphorylation of the intracellular 
domain (McKeehan et al., 1998). FGF signaling can be effectively inhibited by 
SU5402 (3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone) 
which induces a conformational change in the nucleotide-binding loop of the 
tyrosine kinase domain of FGF receptors (Mohammadi et al., 1997). After activation 
of FGFR, the FGF signal can be transduced through the following three signaling 
kinase cascades (Figure 1.1): the Ras/MAP kinase pathway, the PLCy/Ca2+ pathway 
and the PI3K pathway. Each pathway works differently. 
Firstly, in the Ras/MAP kinase pathway, tyrosine phosphorylated FRS2 binds to the 
adapter protein Grb2 and the protein tyrosine phosphatase (PTP) Shp2 (Hadari et al., 
1998; Kouhara et al., 1997). Activated Grb2 forms a complex with the guanine 
nucleotide exchange factor Son of sevenless (SOS). The binding of the Grb2-SOS 
complex to phosphorylated FRS2 allows SOS to activate membrane-bound Ras by 
GTP exchange. Activated Ras leads to the activation of the MAPK signaling cascade 
(Lee and McCubrey, 2002).  
The PLCγ/Ca2+ pathway is activated by FGF signaling when activation of PLCγ by 
binding to phosphorylated tyrosine 766 of FGFR1 occurs (Mohammadi et al., 1992; 
Peters et al., 1992). PLCγ hydrolyzes phosphatidylinositol-4, 5-diphosphate to form 
two second messengers, inositol-1,4,5-triphosphate and diacylglycerol. 
Inositol-1,4,5-triphosphate stimulates the release of intracellular Ca2+ and 
diacylglycerol activates protein kinase C (Doherty and Walsh, 1996; Hall et al., 
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1996). The third pathway activated by FGF signaling is the phosphoinositol-3 kinase 
(PI3K)/Akt pathway: PI3K-Akt pathway can be activated by FGFR, Ras or Grb2. 
FGF signaling was shown to activate down stream targets of transcription factors Ets 
variant gene 4 (ETV4, also called Pea3) and Ets variant gene 5 (ETV5, also called 
Erm) (Brent and Tabin, 2004; Firnberg and Neubuser, 2002; Tsang and Dawid, 
2004). FGF signaling is also required for the expression of ETV4 and ETV5. 
Inhibition of FGF signaling by the FGF inhibitor SU5402 or the overexpression of 
sprouty4 which is a putative intracellular inhibitor of tyrosine kinase signaling 
(Mohammadi et al., 1997) results in a total loss of ETV4 and ETV5 mRNA 
expression (Raible and Brand, 2001).  




Figure 1.1 Intracellular signaling pathways activated through FGFRs (modified from 
(Bottcher and Niehrs, 2005)) 
The activated intracellular signaling cascades include the Ras/MAP kinase pathway (shown 
in blue), PI3 kinase/Akt pathway (shown in green) and the PLCγ/Ca2+ pathway (shown in 
yellow). Proteins connected with two pathways are striped. Members of the FGF 
synexpression group are illustrated in red. 
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1.4.1.2 FGF receptor isoforms 
FGFR1, FGFR2 and FGFR3, can be alternatively spliced, changing the 
carboxy-terminal (C-terminal) half of immunoglobulin-domain III, resulting in either 
the IIIb or the IIIc isoform of the FGFR (Chellaiah et al., 1994; Miki et al., 1992; 
Naski and Ornitz, 1998). These alternative-spliced isoforms show specific 
ligand-receptor binding ability to ligands and the binding appears to be 
tissue-specific (Ornitz et al., 1996). 
1.4.1.3 FGF signaling involved in mouse early embryo development  
FGF signaling in mouse early embryo development has been studied mainly by 
targeted disruptions on FGFs or their receptors. FGF signaling is involved in many 
early developmental processes as identified in the mouse. FGF signaling is essential 
for mouse embryos to develop beyond the 5th cleavage stage and achieve proper 
blastocyst formation. When a dominant negative FGFR was introduced into cleavage 
stage mouse embryos, the embryo stopped developing at the 5th cell division (Chai 
et al., 1998). Other than the non-specific targeting by the dominant negative FGFR, 
some specific targeted mutations have also been carried out. Targeted mutation of 
FGFR1 results in embryonic lethality between day 7.5 and 9.5 days post coitus (dpc), 
showing defects at the onset of gastrulation (Deng et al., 1994; Yamaguchi et al., 
1994). Mouse embryos with a targeted disruption of FGFR2 failed to develop 
primitive endoderm resulting in early post-implantation lethality (Arman et al., 
1998). 
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Other than the previous studies done in mouse embryos, some studies used in vitro 
mESC to study the in vivo ICM, based on the rational that mESC are derived from 
the ICM of the blastocyst and are an equivalent to the ICM. When mESCs are 
cultured in suspension under differentiation conditions, they spontaneously form 
EBs. The earliest structures that become apparent in EB formation is an 
extraembryonic endoderm layer on the outer cells of the EB, this is often used as a 
model of primitive endoderm formation from epiblast. Either Mouse EBs with a 
targeted disruption of FGFR1 (Esner et al., 2002) or a dominant negative FGFR2 (Li 
et al., 2001) fail to form a visceral endoderm and fail to cavitate. 
These FGFR studies provided clear evidence that FGF signaling is critical at the 
earliest stages of mouse embryo development. The FGF required earliest in mouse 
development is Fgf4 as targeted disruption of this gene results in embryonic lethality 
shortly after implantation apparently through a severe ICM proliferation impairment 
(Feldman et al., 1995) which is caused by a defect in the PE (Goldin and 
Papaioannou, 2003; Wilder et al., 1997). This Fgf4 signal presumably emanating 
from the epiblast, it actually was the first described mouse target of Oct4 and Sox2 
(Yuan et al., 1995), appears to signal to both the PE and the TE. It is needed in the 
derivation and culture of trophoblast stem cells; and when Fgf4 is withdrawn, 
trophectoderm stem cells differentiated to other trophoblast subtypes (Tanaka et al., 
1998). The earliest embryonic lethality of any of the other Fgfs is found with Fgf8 
where null embryos fail to gastrulate because of cell migration defects (Sun et al., 
1999).  
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 The above findings show that mice with a disruption in some FGFRs or FGFs fail 
to develop normally in the early embryo. Considering the many essential functions 
of FGF signaling in mouse early development, it is intriguing to investigate the 
functions of FGF signaling in the ICM. As the in vitro equivalence of the ICM, 
mESC can be utilized as a model to study ICM biology providing easier access and 
more material to the limited number of cells within the ICM itself. 
ERK is one of the downstream molecules of the FGF signaling pathway in mESCs. 
mESCs show high ERK activity when they are stimulated to undergo differentiation. 
Fgf4 was found to induce either neural or mesodermal lineage commitment in mESC 
(Kunath et al., 2007; Lowell et al., 2006; Ying et al., 2003b). When FGF signaling 
was inhibited in mESC by the FGFR inhibitor SU5402 or the Erk activating 
enzymes Mek1/2 antagonist PD184352, mESC resisted Fgf4-induce neural and 
mesodermal differentiation or BMP4-induce non-neural differentiation. However, 
mESCs treated with SU5402 or PD184352 showed relatively poor growth and 
viability even though remaining in a pluripotent state (Kunath et al., 2007). When 
the glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021 was further added in 
with SU5402 and PD184352, mESC showed better metabolomic and biosynthetic 
capacity and their growth and viability were restored (Ying et al., 2008). Thus, 
inhibition of these signaling pathways (including FGF) resulted in what these 
authors claim is the ground state of the pluripotent cell. 
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1.4.1.4 FGF signaling involved in hESC  
In complete contrast to mESCs, hESCs require FGF signaling for maintenance. 
Since the first successful derivation of hESC, (Thomson et al., 1998), hundreds of 
hESC lines have been derived. Although these hESC lines are cultured under 
different conditions, FGF2 is routinely added as a critical component into hESC 
medium to maintain pluripotency. The FGF signaling pathway appears to play a 
central role in hESC maintenance , but the exact function of FGF signaling in hESC 
remains unclear, particularly considering FGF2 is endogenously expressed in hESCs 
(Brandenberger et al., 2004). Traditionally, hESCs are cultured directly on MEFs or 
in the MEF conditioned media without direct contact with MEFs. However, for both 
systems, FGF2 is still required even in the presence of MEFs or their secreted 
products, 4ng/ml for on-MEF culture and 12ng/ml for feeder-free culture. It was 
shown that a high dosage of FGF2 (100ng/ml) alone is sufficient to maintain 
pluripotency of hESC without any MEF involvement (Levenstein et al., 2006; Xu et 
al., 2005a). In addition, FGF2 has been shown to increase the clonal derivation 
efficiency and is required for undifferentiated proliferation of hESC (Amit et al., 
2000). 
Transcripts for FGF receptors 1 through 4 are the four major tyrosine kinase 
receptors responsible for transducing the extracellular FGF signal into the cell. 
Microarray, expressed sequence tag (EST) and massive parallel signature sequencing 
(MPSS) profiling data show that these four FGFRs have higher mRNA expression 
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levels in undifferentiated hESCs than in differentiated derivatives {Sperger, 2003 
#174; Sato, 2003 #265; Brandenberger, 2004 #226; Carpenter, 2004 #408; Dvash, 
2004 #407; Ginis, 2004 #404; Rao, 2004 #514; Wei, 2005 #229}. Some important 
downstream regulators of FGF signaling have also been identified in hESCs by 
MPSS, including FRS2, Grb2, and Shp2. Clearly, hESCs are molecularly poised to 
respond to extracellular FGFs. When FGF signaling was inhibited by SU5402, hESC 
differentiated rapidly with an enlarged flattened phenotype (Dvorak et al., 2005; 
Wang et al., 2005). The mRNA expression level of FGFRs in hESCs is 
FGFR1>FGFR3>FGFR4>FGFR2 (Dvorak et al., 2005) 
FGF2 has been shown to execute this function of maintaining hESC pluripotency by 
cooperating with Activin/Nodal (Vallier et al., 2005) and suppressing BMP signaling 
to maintain hESC pluripotency (Xu et al., 2005b). FGF2 inhibits BMP signaling 
activity, although it was unable to inhibit C-terminal phosphorylation of SMAD1 
(Wang et al., 2005; Xu et al., 2005b). However, the inhibitory effect of FGF2 on 
BMP signaling in hESC was shown in cultures with unconditioned medium but with 
Matrigel and serum replacement, both of which contain undefined components. In a 
chemically defined medium, hESC differentiation induced by the FGF inhibitor 
SU5402 was rescued when Activin was added or a Nodal transgene was expressed; 
however, hESC differentiation induced by an Activin receptor Alk4/5/7 inhibitor 
SB431542 cannot be rescued when FGF2 was added (Vallier et al., 2005). Vallier et 
al (2005) also observed that when hESCs were cultured in chemically defined 
medium, BMP4 induced the nuclear localization of phospho-SMAD1/5/8 and 
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increased the transcriptional activity of SMAD1. They also found that FGF2 (40 
ng/ml) did not decrease phospho-SMAD1/5/8 localization in the nucleus or the 
transcriptional activity of SMAD1, suggesting FGF did not inhibit BMP signaling 
directly in hESC cells cultured in chemically defined medium (CDM). In further 
support of this the application of the FGF inhibitor SU5402 (10µM) or the MEK 
kinase inhibitor UO126 (10 µM) (Duncia et al., 1998) in combination with BMP4 
did not increase the nuclear accumulation of phospho-SMAD1/5/8 or the 
transcriptional activity of SMAD1.  
1.4.1.5 Down-stream pathway of FGF signaling in hESCs 
Though a full understanding of the downstream effectors of FGF2 signaling in hESC 
is lacking it has been shown to stimulate the MAPK signaling cascade (Dvorak et al., 
2005), induce gene expression of FOS (Kang et al., 2005), and activate PI3K 
(Armstrong et al., 2006). Relevant to the later, PI3K is known to be important for the 
survival and growth of hESCs (Pyle et al., 2006). 
1.4.2 TGF-β Superfamily of signaling molecules 
The TGF-β family is a group of extracellular signaling molecules that transduce 
signals to cells through their binding of transmembrane receptors which lead to 
activation of cytoplasmic Smad proteins. Upon activation, these Smads enter the 
nucleus and activate (or repress) gene expression. The TGF-β family is grouped into 
two subfamilies according to their sequence similarity and the specific signaling 
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pathways that they activate: the TGF-β/Activin/Nodal subfamily and the BMP/GDF 
(growth and differentiation factor)/MIS (Muellerian inhibiting substance) subfamily 
(Shi and Massague, 2003). 
Extracellular inhibition of the TGF-β family ligands binding to their receptors is 
regulated by ligand traps including 2-macroglobulin (regulates TGF-β), follistatin 
(regulates Activins and BMPs), NOGGIN, Chordin/SOG, and DAN/Cerberus 
(regulates for BMPs). NOGGIN, a representative of ligand traps, antagonizes BMP7 
by blocking the molecular interfaces of the binding epitopes for both type I and type 
II BMP receptors (Groppe et al., 2002). In contrast to ligand traps, accessory 
receptors, or else known as coreceptors, are a group of membrane-anchored proteins 
which promote ligand-receptor binding. The accessory receptor includes betaglycan, 
Cripto and Endoglin. 
1.4.1.1 BMP signaling 
1.4.1.1.1 Effectors of BMP signaling 
The bone morphogenetic proteins (BMPs) are crucial for embryogenesis and tissue 
homeostasis (Chen et al., 2004; De Robertis and Kuroda, 2004; Harland, 2000; 
Schier and Talbot, 2005; Varga and Wrana, 2005). In humans, BMP malfunctions 
cause disorders ranging from bone defects to breast, thyroid and endometrial cancers 
(Harradine and Akhurst, 2006; Massague et al., 2000). BMPs bind a heterodimeric 
receptor complex consisting of a type I and a type II subunit. Three type I receptors 
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(BRIA, BRIB, and ActRI) and two type II (BRII and ActRII) receptors exist (Liu et 
al., 1995; ten Dijke et al., 1994). BMP ligands exhibit a higher binding affinity for 
the extracellular ligand binding domains of the type I BMP receptors than the type II 
receptors; the type I and II receptors bind BMP with higher affinity when they are 
expressed together than when they are expressed separately (Kirsch et al., 2000). In 
contrast to BMP, TGF-β and Activin do not directly interact with the isolated type I 
receptors; they bind to type II receptors to form a complex before recruiting the type 
I receptor (Massague, 1998). Homo or heterodimeric BMP ligands bind to type I 
receptors, inducing a heteromeric complex of type I receptors and type II receptors. 
With the formation of the heteromeric complex, the type II receptors phosphorylate 
the type I receptors. The BMP-bound activated type I receptors then directly 
phosphorylate the downstream molecules SMADs 1, 5 and 8, the BMP Smads, by 
serine-threonine phosphorylation (Kretzschmar et al., 1997b; Macias-Silva et al., 
1996). BMP receptors can also work through a unconventional pathway, conveying 
signals through p38 activation rather than by SMAD phosphorylation (Yu et al., 
2002b). The equivalent Smads in the Activin, Nodal, and TGF-β signaling pathway 
are SMAD 2 and 3. Smad1, 2, 3, 5, and 8 are together referred to as the 
receptor-regulated SMADs or R-SMADs. This is in contrast to the co-Smad (Smad4) 
which binds all R-Smads and to the inhibitory Smads, Smads 6 and 7 (see below). 
The activating phosphorylation event in the R-SMADs occurs at the two serine 
residues within the flexible SSXS motif at the C-terminal end (Abdollah et al., 1997; 
Souchelnytskyi et al., 1997). After activation by C-terminal phosphorylation, 
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R-SMADs bind to SMAD4 (the co-SMAD) and then translocate to and accumulate 
in the nucleus and function as transcription factors. Another four MAPK 
phosphorylation sites (PXSP motifs) are located within the linker region which 
connects the two conserved globular domains (MH1 and MH2 domains) found in 
R-Smads. There is also a PPAY motif that binds ubiquitin ligases, SMAD 
ubiquitination regulatory factors (SMURFs), just downstream of the PXSP motif 
(Zhu et al., 1999). ERK activation downsteam of the FGF/Ras/MAPK cascade was 
recently shown to enable MAPK phosphorylation of the PXSP motifs in the linker 
region of SMAD1. This phosphorylation enables SMURF1 binding to SMAD1 and 
subsequently attenuates SMAD1 signaling to the nucleus through two mechanisms. 
The first is through binding of SMURF1 to SMAD1 causing SMAD1 ubiquitination 
leading to proteasome-mediated degradation (Zhu et al., 1999). The second 
mechanism is thought to work through SMURF1 competition with Nucleoporin for 
binding to the Smad1 linker region. This leads to SMAD1 cytoplasmic retention as 
the direct interaction of Nucleoporin is required for Smad nuclear translocation 
(Kretzschmar et al., 1997a; Sapkota et al., 2007; Xu et al., 2002a). For the TGF-beta 
Smads (2 and 3) the degradation mechanism differs slightly. Ubiquitination and 
degradation of activated SMAD2 appears to be mediated by SMURF2 in the nucleus 
(Lin et al., 2000; Lo and Massague, 1999; Zhang et al., 2001) while ubiquitination of 
activated SMAD3 has been shown to be mediated by the SCF/Roc1 complex E3 
(Fukuchi et al., 2001). 
SMAD6, an Inhibitory SMAD (I-SMAD), inhibits the function of R-SMADs by 
   
 
48
competing with R-SMADs for binding to SMAD4, thus inhibiting BMP signaling 
(Hata et al., 1998; Imamura et al., 1997). The other I-SMAD, SMAD7, competes 
with R-SMAD to bind to activated TGF-β type I receptor, leading to receptor 
degradation and inhibition of the R-SMAD phosphorylation (Hayashi et al., 1997; 
Kavsak et al., 2000; Nakao et al., 1997; Suzuki et al., 2002). SMAD7 can also 
cooperate with the E3 ubiquitin ligases, the Smurfs, to ubiquitinate the receptors and 
cause receptor degradation (Ebisawa et al., 2001; Tajima et al., 2003).  
1.4.1.1.2 Transcriptional targets of BMP signaling 
As the predominant mechanism of action of BMP-Smad signaling is through the 
alteration of transcriptional regulation, it is of particular interest to identify the 
transcriptional targets of this signaling. The expression of Inhibitor of DNA binding 
1 (Id1) can be enhanced by binding of a SMAD1–SMAD4 complex onto the Id1 
promoter region which includes an overlapping GC and SMAD-binding elements 
(GTCT) (Lopez-Rovira et al., 2002). Transcription factor SMADs were shown to 
bind directly to specific DNA motifs (Shi and Massague, 2003; ten Dijke et al., 2000; 
Zwijsen et al., 2003). R-SMADs and SMAD4 bind to the SMAD binding element 
(SBE) motif GTCT (Shi et al., 1998) and GTCTG exists in the promoters of most 
TGF-β and BMP target genes. Based on the phylogenetic conservation of the 
BMP-responsive element [BRE, TGGCGCC(A)] and SBE [GTGT(G)], with spacing 
in between ranging from 3 bp to 60 bp, novel BREs in other BMP target genes were 
predicted from a Xenopus study. Genes containing both the BRE and SBE are 
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predicted to be direct target genes of SMAD: Bambi, Smad7, Id1, Id2, Id3, Id4, Msx1, 
Msx2, Gata2, Gata3, Bmpr2, Tlx2, Ventx and Tbx2 (Karaulanov et al., 2004). 
Among them, the MSX2 (homeobox gene msh homeobox 2) may regulate 
epithelial-mesenchymal cell interactions in the human placenta. It was found to be 
expressed in the cytotrophoblast cells in the first trimester human placenta and in the 
syncytiotrophoblast of the term placenta (Quinn et al., 2000). Msx1 is expressed in 
the mouse uterus during the periimplantation period, suggesting its role in the 
implantation process (Daikoku et al., 2004). Msx1 and Msx2 are co-expressed with 
BMPs in many tissues and are immediate targets of BMP signaling (Hollnagel et al., 
1999). On the other hand, BMP4 expression during mammalian palatogenesis and 
tooth development is regulated by Msx1 although BMP4 signaling appears capable 
of bypassing Msx1 (Zhang et al., 2002). 
BMP targets of relevance to my thesis include the transcription factor homeobox 
gene MSX2 as it is expressed in the cytotrophoblast cell of human placenta and it 
may regulate epithelial-mesenchymal cell interactions in the human placenta (Quinn 
et al., 2000). Id family genes are responsive to BMP signaling and play critical roles 
in many developmental processes including placental development, and for the 
maintenance of ES cell pluripotency (Hollnagel et al., 1999; Locklin et al., 2001; Ota 
et al., 2002). Dlx3 is shown to be regulated by BMP signaling because it negatively 
responds to the BMP antagonists chordin or the truncated BMP receptor (Suzuki et 
al., 1994). Dlx5 was also shown to be a target of BMP4 in Xenopus (Miyama et al., 
1999).  
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1.4.1.1.3 BMPs in mESC 
BMP signaling appears to have multiple effects in mESC cultures both in the 
differentiation process and in maintaining the undifferentiated state, this presumably 
paralleling the multiple roles BMP signaling is known to play in embryonic 
development. Bmp4 appears to be able to enhance the mesodermal differentiation in 
mouse embryos and in mESCs (Johansson and Wiles, 1995; Kawasaki et al., 2000; 
Winnier et al., 1995) presumably through an activative role in suppressing the 
neuronal lineage. This is shown through the Bmp4 antagonist NOGGIN which 
increases neuroectodermal formation when included in mESC differentiation 
cultures (Finley et al., 1999; Gratsch and O'Shea, 2002). In addition, the direct 
binding of Nanog to Smad1 can also prevent differentiation towards a neural fate 
(Suzuki et al., 2006). These studies indicate BMP signaling as actively suppressing 
the neuroectodermal lineage. 
In the absence of LIF, mESCs treated with Bmp4 (0.25–10 ng/ml) differentiate into 
the mesodermal lineage (Czyz and Wobus, 2001) whereas neuronal differentiation is 
blocked (Finley et al., 1999). In the presence of LIF, low concentrations of Bmp4 
can up-regulate Id and inactivate ERK/MAPK. This leads to a suppression of 
differentiation while sustaining self-renewal of mESCs (Qi et al., 2004; Ying et al., 
2003a) indicating an active role for BMP4 in maintaining mESC cultures. 
In support of the Bmp4 effect for supporting mESC pluripotency, the BMP 
downstream molecule Id can bypass the BMP effect. When Id is over-expressed, 
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mESC can be maintained with LIF without serum, bypassing BMP signals; when 
LIF is removed, Id-overexpressing mESCs differentiate into mesodermal and 
endodermal lineages. However, neural differentiation is blocked (Ying et al., 2003a).  
The transcription factor Brachyury (T) is up-regulated when mesodermal 
differentiation is induced by Bmp4 in mESC. Nanog expression is up-regulated 
when T and Stat3 coordinately bind to the Nanog promoter. Up-regulated Nanog 
binds to Smad1 and results in interfering of recruitment of Smad1 coactivators, thus 
blocking Smad1 downstream transcriptional targets, including T. This self-regulatory 
circle stabilizes the pluripotent state of mESC when BMP signal is at low level.  
The co-Smad, Smad4, is assumed to be essential to transmit both the BMP Smads (1, 
5, and 8) and the TGF-beta Smads (2 and 3) signal to the nucleus. As Smad4 knock 
out mouse embryos die after implantation by embryonic day 7.5 with gastrulation 
defects and ES cells can be derived readily from the ICM of these mutants (Sirard et 
al., 1998), it would appear that Smad signaling is not essential for mouse 
development until gastrulation. This also indicates that BMP signaling transduced 
through SMAD is not necessary for ES pluripotency. However, when either Bmp 
type I receptor Alk3 or type II receptor BmprII is inactivated, mouse embryos die 
before gastrulation (Beppu et al., 2000; Mishina et al., 1995). BMP signaling can 
also be transduced via the MAPK family member p38 along a complex set of adapter 
proteins including Xiap, Tab1/2 and Tak1 (Iwasaki et al., 1999; Yamaguchi et al., 
1999). Consequently, when p38 is inhibited using SB23580, mESCs can be derived 
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from Alk3 mutant embryos. The p38 inhibition simulates BMP induced 
de-phosphorylation of p38. However, these mESC can self-renew without the 
continued presence of SB203580, this may be due to the up-regulation of Alk1 and 
Alk2 which functionally compensates for the loss of ALK3 (Qi et al., 2004) 
Blocking of Activin/Nodal/TGF-β signaling by I-Smad Smad7 or the inhibitor 
SB431542 (a synthetic molecule that inhibits the kinases of receptors for 
Activin-Nodal-TGF-β but not those of BMPs) significantly decreases ES cell 
proliferation without interfering with mESC pluripotency. On the other hand, 
blocking of BMP signaling by I-Smad Smad6 does not show significant effects on 
mESCs (Ogawa et al., 2007). 
1.4.1.1.4 BMPs in hESC 
Similar to the contrast between mESCs and hESCs with regard to FGF signaling, 
hESCs respond strikingly different to BMPs than mESCs do. In undifferentiated 
hESCs, the TGFβ/Activin/Nodal signaling pathway is constantly activated and 
necessary to maintain hESC pluripotency through SMAD2/3 activation while the 
BMP/GDF signaling pathway remains unphosphorylation, inactive, and within the 
cytoplasm (James et al., 2005). Activin A was secreted by mouse embryonic feeders 
and Activin A was shown to be able to maintain the pluripotency of hESC without 
the presence of FGF2 (Beattie et al., 2005). The SMAD2/3 activation occurs upon 
the reduced activity of SMAD1/5, suggesting that TGFβ/Activin/Nodal can 
negatively regulate BMP4 in hESCs. Upon early differentiation, SMAD2/3 signaling 
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is down-regulated while SMAD1/5 signaling is activated (James et al., 2005). 
Inhibition of Activin/Nodal signaling by the Activin receptor inhibitor SB431542 
induces hESC differentiation however, the inhibition of Nodal using antagonists 
Lefty and Cerberus-Short causes hESC differentiation in prolonged culture but 
cannot induce immediate differentiation (Vallier et al., 2005). The role of TGF-β in 
maintaining hESC pluripotency was shown to involve TAZ which binds heteromeric 
SMAD2/3–4 complexes and regulates their accumulation and target gene 
transcription activation in nucleus (Varelas et al., 2008). 
Differing concentrations of BMP2 (300ng/ml), BMP4 (100ng/ml) or BMP7 
(300ng/ml) can effectively induce hESC to differentiate towards trophoblast lineage 
(Xu et al., 2002b). On the contrary, suppression of BMP signaling with NOGGIN 
(500 ng/ml) incorporated with a medium-level dosage of FGF2 (40 ng/ml) supports 
the undifferentiated proliferation of hESC in the absence of feeder cells (Wang et al., 
2005; Xu et al., 2005b). However, another study showed that BMP induces hESC to 
differentiate towards extra-embryonic endoderm and the BMP antagonist NOGGIN 
shifts the differentiation towards neural precursors (Pera et al., 2004). A further study 
also showed that NOGGIN enhances the hESC differentiation towards 
neuroectodermal precursors (Sonntag et al., 2007). 
GDF3, believed to be a BMP inhibitor, is highly expressed in hESC and is 
down-regulated dramatically when hESCs differentiated (Sato et al., 2003). 
Over-expression of GDF3 contributes to the undifferentiated status of hESCs 
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(Levine and Brivanlou, 2006). Lefty-A and Lefty–B are secreted inhibitory ligands 
(Schier and Shen, 2000) in the TGF-β pathway and they are also highly expressed in 
hESCs (Sato et al., 2003). Lefty 1, a mouse homolog of Lefty-A, was reported to be 
one of the downstream target genes for the key ESC transcription factor Pou5f1.  
In a comparative experiment on supportive and non-supportive human feeder cells, 
the BMP4 pathway inhibitor Gremlin 1 (GREM1) was found to be highly enriched 
in supportive MEFs (Kueh et al., 2006), which probably contributed to the 
maintenance of pluripotency of hESC by acting as an antagonist to differentiation 
caused by self-produced BMP4 by hESC. 
1.5 Specific aims of this study 
hESCs have great clinical potential for cell-based therapies as they give rise to 
virtually all cell types. The great challenge is how to direct hESCs towards the 
desired cell type. Despite this there remain many basic questions unanswered 
regarding the regulation of differentiation and the earliest signals initiating these 
events from the undifferentiated ES cell. 
In addition to the relevance to cell-based therapies, hESCs provide an ideal model 
system for understanding the earliest events in human development particularly 
considering hESCs ability to readily generate the trophoblast lineage. 
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FGF signaling plays a central and critical role in maintaining pluripotent hESC, 
however, the underlying mechanism is still unknown. Therefore, a proper 
understanding of FGF signaling in hESC could provide insight into how hESC 
maintain and lose their pluripotency. By inhibiting FGF signaling, differentiated 
hESCs will be characterized to identify which cell lineage is forming. Other known 
methods for directing hESC differentiate along the same lineage will be compared. 
In particular, BMP4 exerts a highly similar effect on hESC as FGF signal inhibition, 
both inducing hESC differentiate towards trophoblast cell lineage. The relationship 
between FGF signal inhibition and BMP4 for inducing hESC differentiate along the 
trophoblast cell lineage will be investigated. By integrating the FGF signal inhibition 
and BMP4, a method for efficiently directing hESC differentiation towards the 
trophoblast lineage will be established. 
The specific aims of my thesis are to identify the roles of primarily FGF but also 
BMP signaling in hESC culture and how the manipulation of these plays into the 
first molecular events in differentiation. By probing these pathways in hESC, 
considering the contrast in the effects between mESC and hESC of both these 
signaling molecules, I aimed to gain a better understanding of the developmental 
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2.1 Cell culture 
2.1.1 Mouse embryonic fibroblasts (MEFs) 
2.1.1.1 Derivation of MEFs  
Primary cultures of MEFs were derived from E13.5 mouse embryos of CF-1 strain. 
Brains and hearts were removed from harvested embryos prior to mincing the 
remaining carcasses with dissecting scissors into grain sized pieces and, 
subsequently, treated with trypsin to achieve a single cell suspension. Trypsin was 
inactivated upon addition of MEF media (90% high-glucose Dulbecco’s modified 
Eagle’s media (DMEM) (GIBCO, Cat#11960, high Glucose 1X), supplemented with 
10% FBS (Bench MarkTM, Cat#100-106), 0.1 mM non-essential amino acids (NEAA) 
(GIBCO, Cat#11140) and Penicillin (100 unit/ml)/ Streptomycin (100 µg/ml; 
GIBCO, Cat#15140)) and the cells plated onto tissue culture dishes. The next day, 
the cells were examined and any substantial clumps were removed. When the cell 
confluency reached 90% the MEFs were harvested and stored as Passage 1 (P1) 
MEFs in cryopreservation media (60% DMEM, 20% DMSO and 20% FBS) first at  
-80°C overnight and then subsequently transferred to liquid nitrogen for long term 
storage. 1 vial of P1 MEF was further cultured to P5 and was used as feeders for 
hESCs to test its capability for supporting undifferentiated hESC. The capability of 
derived MEF for supporting undifferentiated hESC was confirmed by 3 successive 
passages of hESC over 3 weeks of culture. For each testing of MEF, the same 
passage of MEF is used. 




2.1.1.2 Culture of primary MEF 
To expand MEFs for use cells were plated onto 0.1% (w/v) gelatin-coated tissue 
culture dishes and allowed to expand over 4 or 5 passages. These expanded MEFs 
were subsequently mitotically inactivated with 10µg/ml mitomycin C (Kyowa, 2mg) 
for 2.5 hours prior to use as feeder support for ES cell culture.  
2.1.2 Mouse ES cell culture  
The mESC line E14 (ATCC, Manassas, VA: CRL-1821) was maintained in an 
undifferentiated state by culturing the cells on a feeder layer of inactivated MEFs in 
mESC medium or in feeder-free condition with the presence of LIF (1000 u/ml) on 
0.1% gelatin-coated culture plate in feeder-free mESC media. The mESC medium 
consisted of 85% DMEM (GIBCO, Cat#11960), supplemented with 15% 
ES-qualified-FBS (GIBCO, Cat# Cat # 16141-079), and 0.1 mM NEAA(GIBCO, 
Cat#11140), 0.1 mM 2-mercaptoethanol (GIBCO, Cat#21985-023), Penicillin (100 
unit/ml)/ Streptomycin (100 µg/ml, GIBCO, Cat#15140), and 1 mM L-glutamine 
(GIBCO, Cat#25030). The feeder-free mESC medium consisted of 80% DMEM 
(GIBCO, Cat#11960), supplemented with 20% ES-qualified-FBS, and 0.1 mM 
NEAA (GIBCO, Cat#11140), 0.1 mM 2-mercaptoethanol, Penicillin (100 unit/ml)/ 
Streptomycin (100 µg/ml, GIBCO, Cat#15140), 1 mM L-glutamine and 1,000 
units/ml of LIF. 




2.1.3 Human ES cell culture  
Prior to any experimentation it was essential to establish, in my hands, the ability to 
grow and maintain good hESC cultures. At the beginning of my studies it was still 
relatively early days in hESC experimentation with the first report of hESC 
derivation having occurred less then 5 years previous. hESC lines derived from 
different groups were grown under different media conditions, strains of mice that 
generated supportive MEFs varied between hESC lines, even the method of passage 
varied from collagenase digestion to manual picking of colonies. Thus the initial 
stages of my work was to derive supportive MEF (Figure 2.1A) and to establish 
culture conditions that were consistent between lines while maintaining the 
undifferentiated state, with a stable and normal karyotype, but still retaining the 
ability to differentiation when placed in appropriate culture conditions.  
Two human ES cell lines were routinely used throughout this study, the male H1 line 
(WA01 under NIH nomenclature) derived by Thomson et al. (1998) and a female 
line, HES2 (ES02 under NIH nomenclature), obtained from ES Cell International Pte 
Ltd (Singapore) and initially derived by Reubinoff et al (Reubinoff et al., 2000). 
With these two lines representing both sexes and derived by two independent groups 
I was able to verify that any observations made were not specific to a particular 
hESC line. The protocol provided by the supplier of the HES2 line recommended 
manual dissection as the method to passage these cells, in addition, the media 
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composition was different to that recommended by the supplier of the H1 line. For 
experimental consistency I first established the HES2 line grown in H1 media and 
passaged by collagenase. Under these culture conditions this line, in addition to the 
H1 line, was shown to maintain good undifferentiated morphology (Figure 2.1A), 
maintain normal karyotypes (Figure 2.1B), and maintain the expression of three 
pluripotent markers, OCT4, SSEA4 and TRA-1-60, as detected by 
immunofluorescence staining (Figure 2.2).  
The hESC cell line WA01 (WiCell H1) was obtained from WiCell Research Institute 
(Wisconsin, USA) and hESC cell line ES02 (ESI HES2) was obtained from ES Cell 
International (Singapore). Both cell lines can be maintained in an undifferentiated 
state by culturing the cells at 37°C in a humidified atmosphere of 95% air and 5% 
CO2 either on feeders or feeder-free, details of each method are provided below. For 
both methods cells were generally passaged every 7 days at variable ratios (1:3-6) 
depending on their condition. Cells were disrupted by incubating with 1mg/ml 
collagenase type IV (GIBCO, Cat#17104019) for 6-8 minutes at 37oC. After the 
edges of hESC colonies appeared separated from the plate surface, a 1ml serological 
pipette was used to scrape colonies off the plate and the collagenase solution was 
gently pipetted up and down several times to break colonies into smaller cell clumps 
of about 1mm in diameter. The cell suspension was then centrifuged at 800 
revolution per minute (rpm) in a centrifuge (Eppendorf, Cat#5810R) for 1 minute 
and the hESC pellet was resuspended in an appropriate amount of hESC media to 
achieve the desired split ratio. This cell suspension was then plated onto 6-well 
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plates, 2 ml per well, and media was changed daily. Cell photos were taken by a 
Nikon CoolPix 4500 digital camera on a Nikon phase contrast microscope 
(ECLIPSE, Cat#TS100). 




Figure 2.1 Culture and karyotyping of pluripotent hESC 
Two hESC lines, both H1 and HES2 were maintained in a self-renewal state, their karyotype 
and pluripotency markers were routinely examined. (A) MEFs that I derived (left panel); H1 
hESCs cultured on MEFs (middle panel), note the spindle-like morphology of MEFs is 
caused by FGF2 in the hESC media; HES2 hESCs cultured on MEF (right panel). (B) 
Karyotypes of H1 hESC (left panel) and H1 hESC (right panel), done by Dr Palanisamyn of 
molecular cytogenetics laboratory (GIS in-house lab). 




Figure 2.2 Immunostaining of pluripotency markers of hESC, cultured on MEF.  
Indirect immunofluorescence detection of pluripotency markers POU5F1, SSEA4, and 
TRA-1-60 in WiCell H1 hESC. Upper panels – negative control, only the secondary 
antibodies were stained. Lower panels – both primary and secondary antibodies used. 
 
   
 
64
To examine the hESC’s ability to differentiate I used the well established method of 
embryoid body formation and analyzed lineage marker gene expression at different 
times of differentiation. Cell clumps of both WiCell H1 and ESI HES2 were cultured 
for 6 days, 12 days and 17 days respectively to form hEBs of different stages (Figure 
2.3). The mRNA expression level of hEBs derived from H1 and ESI hESC was 
examined by Taqman real time PCR and indicated the up-regulation from 
undifferentiated hESC of genes representative of multiple lineages (Figure 2.4) 
indicating hESC cultures of both lines remained pluripotent (Figure 2.4). 
 
Figure 2.3 Embryoid bodies derived from hESC. 
EBs were derived from both H1 and HES2 hESC lines. The length of time in suspension 
culture from the initial undifferentiated hESC is indicated in days. Note cystic cavities 
forming in the later EBs. 
 




Figure 2.4 mRNA expression profiling of human EBs. 
Taqman real time PCR gene expression profiling of WiCell H1 (upper panel) and ESI HES2 
(lower panel) undifferentiated ES cells (ctrl) and 6 (6DEB), 12 (12DEB), and 17 (17DEB) 
day embryoid bodies. A and B represent biological replicates. In EBs from both cell lines, 
the hESC marker POU5F1 was down-regulated and the endoderm marker AFP, the 
trophectoderm marker CDX2, the ectoderm marker NES and the mesoderm marker T were 
up regulated. The germ cell marker SCP3 was slightly down regulated. The Ct values 
indicated are those from the undifferentiated hESC which all others were expressed relative 
to. The Y-axis shows the fold change compared to the control on log10 scale. ACTB was used 
as the endogenous control. All values were derived from technical triplicates.  
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The above analysis, provided confidence that the samples used were well 
characterized hESCs expressing appropriate markers of pluripotent cells, were 
karyotypically normal, and presumably had the ability to differentiate into multiple 
cell types based on marker mRNA expression in EBs. 
2.1.3.1 Culture of hESC on MEF 
The hESC culture media consisted of 80% DMEM/F12 (GIBCO, Cat#11330) 
supplemented with 20% KnockoutTM serum replacement (KOSR; GIBCO, 
Cat#10828), 1mM L-glutamine, 0.1mM nonessential amino acids (GIBCO, 
Cat#11140), 0.1mM β-mercaptoethanol (Sigma, Cat#M7154) and 4 ng/ml FGF2 
(Invitrogen, Cat#13256029). Mitomycin C inactivated MEFs were plated at a density 
of 0.2x105 cells/cm2 with MEF media. The next day, after confirmation of healthy 
MEF by morphological observation, MEF media was removed and hESCs were 
plated on the MEF feeder layer with hESC media (Figure 2.5A). Plated MEFs 
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2.1.3.2 Culture of feeder-free hESC  
MEF-conditioned media (CM) was produced with little modification from Xu et al. 
(Xu et al., 2001). On the 1st day, 4x106 inactivated MEFs were plated on a 
gelatin-coated 150cm tissue culture dish. On the 2nd day, after MEFs were attached 
to the dish bottom, MEF media was replaced by hESC media. The hESC media was 
collected and replenished daily up to the 11th day. The volume of hESC media 
applied to MEF culture changed from 40ml on the 3rd-5th day, 30ml on the 6th-8th day 
and 20ml on the 9th-11th day. All CM was collected in an empty sterile bottle and the 
combined CM was passed through a 0.22 µm filter. After filtering, CM was then 
supplemented with 8 ng/ml FGF2 and mixed thoroughly, so as to get the final 
working CM. Feeder-free hESC were then cultured with this final 
FGF2-supplemented CM and this changed daily.  
Stock Matrigel (BD, Cat#354234) was diluted at 1:2 ratio with KnockoutTM D-MEM 
(GIBCO, Cat#10829) and 2 ml aliquots were stored at -20oC. Each 2ml Matrigel 
aliquot was diluted at 1:15 ratio with KnockoutTM DMEM to get a final dilution of 
1:30. To coat tissue culture plates for feeder-free hESC culture, diluted Matrigel was 
dispensed onto culture plates to cover the bottom and then removed for reuse. 
Coated plates were put in a 37oC incubator for 10 minutes to solidify the Matrigel 
coating. Matrigel coating and the 10 minute incubation were repeated two additional 
times before hESCs were grown on these Matrigel coated plates (Figure 2.5B).  
   
 
68
The majority of experiments presented in this thesis used feeder-free cultures of both 
the H1 and HES2 hESC lines. This was to avoid hESC being contaminated with 
MEFs for subsequent biochemical and molecular analyses. The minority of 
experiments where hESCs were cultured on MEF are experiments reported in Figure 
2.1, Figure 2.2, Figure 3.1, Figure 3.3, and Figure 3.4. 
 
Figure 2.5 The hESC culture.  
(A) WiCell H1 hESC grown on a MEF feeder layer (6 days post-passage) (B) Feeder-free 
H1 hESC culture (6 days post-passage), the fibroblast-like cells are differentiated hESCs. 
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2.1.3.3 Cryopreservation of hESC 
hESCs were incubated with 1mg/ml collagenase type IV for 6-8 minutes at 37oC. 
After the edges of colonies were separated from the plate surface, a 1ml serological 
pipette was used to scrape colonies off the plate and to gently pipette the cell 
suspension up and down several times to break colonies into smaller cell clumps of 
about 2mm in diameter. Cells were then pelleted by centrifugation at 800 rpm for 1 
minute and then resuspended in freezing media. Freezing media consists of 30% 
fetal bovine serum, 10% dimethylsulfoxide (DMSO; Calbiochem, Cat#572630) and 
60% hESC media or CM according to the on-MEF culture or the feeder-free culture, 
respectively. 
2.1.3.4 Karyotyping  
Karyotypes of both H1 and HES2 were examined by our in-house karyotyping 
laboratory routinely. Cells at about 80% confluency were treated with colcemid for 
mitotic arrest and harvested by standard hypotonic treatment and methanol: acetic 
acid (3:1) fixation. Slides were prepared by a standard air drying method and G- 
band karyotyping was performed according to the protocols established in the 
karyotyping laboratory. 
2.1.4 Human embryoid body (EB) culture 
hESCs were treated with collagenase and the cell clumps were resuspended in EB 
media with 80% Knockout D-MEM (GIBCO, Cat#10829-018),1 mM L-glutamine, 
0.1 mM β-mercaptoethanol (GIBCO, Cat#21985-023), 1% NEAA (GIBCO, 
Cat#11140) and 20% FBS. EBs were cultured in suspension by plating in Petri 
dishes. Media was changed daily. 
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2.2 Bioactive molecule treatments 
All the bioactive molecules used in this study were supplemented into the hESC 
media. This media all included the FGF2. FGF inhibitor SU5402 (CALBIOCHEM, 
Cat#572630) was initially dissolved in DMSO to a concentration of 25mg/ml and 
added to hESC media to achieve a final concentration of 20 µM. BMP4 (R&D 
Systems, Cat#314-BP/CF) was initially dissolved in PBS to get a stock of 100,000 
ng/ml and then added to hESC media to achieve a final concentration of 100 ng/ml. 
Combination treatments consisted of 20 µM SU5402 and 100 ng/ml BMP4. Noggin 
(R&D Systems, Cat#3344-NG) was initially dissolved in PBS at a concentration of 
100 µg/ml and added to hESC media to achieve a final concentration of 500 ng/ml. 
For each treatment and at each time point, there were biological replicates. Untreated 
cells which are only treated with DMSO of the same concentration were set as 
biological control. 
2.3 RNA analysis 
2.3.1 RNA isolation 
Total RNA was isolated by homogenizing cells in TRIzol (Invitrogen, 
Cat#15596018) followed by subsequent purification using the RNeasy Mini kit 
(Qiagen, Cat#74106). For one well of a 6-well-plate of confluent cells, 1ml of 
TRIzol was added. After the cells were fully homogenized, 0.2 ml chloroform was 
added and the samples were vortexed for 3 minutes. After centrifuging at 12,000 rpm 
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(Eppendorf, Cat#5415R) at 4°C for 15 minutes, the aqueous phase was mixed with 
0.5 ml isopropanol and incubated at room temperature for 10 minutes. After 
centrifuging at 12,000 rpm at 4°C for 10 minutes, the pellet was washed with 1 ml 
75% ethanol and then centrifuged at 10,000 rpm at 4°C for 5 minutes. After fully 
dissolving the pellet with 100 µl RNase-free H2O, 350 µl buffer RLT from the 
RNeasy Mini kit (freshly add 10 µl 2-Mercaptoethanol in 1ml RLT) was added and 
mixed thoroughly. 250 µl 100% ethanol was added and mixed thoroughly by 
pipetting. The sample was transferred (700 µl) to a RNeasy mini column placed in a 
2 ml collection tube and centrifuged for 15 seconds at approximately 10,000 rpm. 
After discarding the flow-through, 500 µl buffer RPE was added onto the RNeasy 
column and centrifuged for 15 seconds at approximately 10,000 rpm. To wash 
thoroughly, the previous step was repeated. The RNeasy column was transferred to a 
new 1.5 ml collection tube and 20 µl RNase-free H2O pipetted directly onto the 
RNeasy silica-gel membrane. After 5 minutes, the column was centrifuged at >=10 
krpm for 1 minute to elute. The column was washed again to collect last traces of 
RNA by adding another 10~20 µl RNase-free H2O. The concentration and purity of 
the total RNA was determined by a Spectrophotometer (Thermo Scientific 
NanoDropTM, Cat#ND-1000) according to the ratio of 260/280. Extracted RNAs 
were stored at -80°C. 
2.3.2 RNA integrity analysis 
RNA integrity was examined with the RNA 6000 Pico Assay run on the Agilent 
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2100 bioanalyzer (both from Agilent Technologies). 
2.3.3 Reverse transcriptase (RT) 
1 µg of total RNA was reverse transcribed into complementary DNA (cDNA) using 
the High Capacity cDNA Reverse Transcription Kit (ABI, Cat#4368813) in a 20 µl 
reaction mixture consisting of RT Buffer, dNTPs, random primers and Multiscribe 
reverse transcriptase, incubated at 25°C for 10 minutes and then at 37°C for 2 hours. 
The product of RT was further processed by conventional polymerase chain reaction 
(PCR) or Taqman real time PCR. 
2.3.4 Polymerase chain reaction (PCR) 
2.3.4.1 Conventional PCR 
cDNA was amplified for end-point PCR with gene-specific primers by a 
thermocycler machine (ThermoHybaid, UK). PCR products were electrophoresed on 
a 1% (w/v) agarose gel which was dissolved in TBE buffer by heating. For 100 ml of 
gel solution, 2 µl of 1 µg/µl ethidium bromide (EtBr) was added. Products of reverse 
transcription-polymerase chain reaction (RT-PCR) were loaded with 7 µl loading 
buffer (0.1% xylene cyanol in 30% glycerol) and electrophoresed at 80 V for 45 
minutes in TBE buffer. The gels were examined and photographed with an 
ultraviolet trans-illuminator (Syngene Bio Imaging System).  
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2.3.4.2 Taqman real time PCR  
Real time PCR was performed by ABI PRISM® 7700 and 7900 Sequence Detection 
System (Applied Biosystems). There were biological duplicates for each treatment 
and every sample was run in technical triplicate. TaqMan primer-probe sets were 
ordered from Applied Biosystems. Threshold cycle (CT) values of experimental 
targets were normalized to beta actin (ACTB), the endogenous house-keeping control, 
and untreated hESC were used as the biological control so as to understand the 
changes upon treatments. Data was analyzed using ABI SDS 2.2 software (Applied 
Biosystems). 
2.3.5 Microarray analysis 
Samples were prepared in biological replicates. 500 ng total RNA was subjected to 
reverse transcription, second strand cDNA synthesis and in vitro transcription (to 
amplify RNA), using Illumina® TotalPrep™ RNA Amplification kit (Ambion, USA, 
Cat#IL1791). The resultant amplified RNAs were hybridized on Sentrix® Human 
Ref-8_V2 Expression BeadChip which covered approximately 24,000 RefSeq 
transcripts for whole-genotyping expression assay (Illumina, USA, Cat#BD 25-213), 
washed and scanned with Illumina BeadStation according to the Illumina protocols. 
Microarray raw data was extracted by BeadStudio software (Illumina) with 
background subtraction and subsequently analyzed by GeneSpring GX (Agilent 
Technologies). The significance of expression changes were determined by T-test P 
value <0.05.  
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2.4 Protein analysis 
2.4.1 Protein extraction and quantitation 
The cell lysis buffer consisted of 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 150 
mM NaCl, 1mM ethylenediaminotetraacetic acid (EDTA), 2mM NaVO3, 10mM 
PMSF and protease inhibitor (Roche, Cat#11697498001). The cell lysis buffer was 
applied directly onto cells that had been briefly rinsed in PBS but were still attached 
to the culture plate to obtain total cell protein lysates. Cells were lysed on ice before 
being centrifuged at 13,200 rpm for 30 min at 4°C. 4X protein loading buffer was 
added to the protein lysate and then boiled at 95 °C for 5 minutes. Equal amounts of 
total protein were determined by the Quick Start™ Bradford Protein Assay 
(BIO-RAD, Cat#5000205). 
2.4.2 Western blot 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at constant 0.05 A for 30-45 minutes with a mini-gel 
apparatus (Mini-Protean II, BioRad Laboratories, Hercules, CA). The percentage of 
SDS-polyacrylamide gel was adjusted according to the protein size. After protein 
separation by SDS-PAGE, proteins were transferred onto a nitrocellulose membrane 
(Hybond-Enhanced Chemiluminescence (ECl), Cat#RPN3032D-ZMII, Amersham, 
Biosciences) by electroblotting (BioRAD Mini PROTEAN® 3 Cell, Cat#525BR) at 
constant 0.2 A for 2 hours or 0.08 A overnight. After transferring, the nitrocellulose 
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membrane was stained with Ponceau to check whether the protein transfer was 
successful. After washing away the Ponceau, the nitrocellulose membrane was 
blocked in 5% non-fat milk in Tris-buffered saline-Tween20 (TBS-T) for 30 minutes. 
After blocking, the nitrocellulose membrane was incubated overnight at 4°C with 
primary antibodies. Next the membrane was washed with TBS-T for 20 minutes, 
followed by secondary antibody incubation for 2-4 hours at room temperature. 
Primary antibodies used in this thesis for western blot were: ID2 (Santa Cruz, 
Cat#sc-489), KRT18 (Santa Cruz, Cat#sc-6259), GAPDH (Chemicon, 
Cat#MAB374), Nanog (Chemicon, Cat#ab5731), and POU5F1 (Santa Cruz, 
Cat#sc-8628). Horse radish peroxidase (HRP)-conjugated secondary antibodies were: 
goat-anti-rabbit HRP (Pierce, Cat#31460), goat-anti-mouse HRP (Pierce, Cat#31430) 
and rabbit-anti-goat HRP (Santa Cruz, Cat#SC-2768). Chemiluminescence was 
detected by SuperSignal West Pico Chemiluminescent Substrate (Pierce, Cat#34078) 
and photos were taken digitally by a luminescent imager (BIO-RAD, Versa Doc, 
Cat#MP 5000).  
2.4.3 Immunostaining 
Cells were cultured on chamber slides (NUNC, Cat#177429) coated with Matrigel. 
Cells were fixed with 4% (w/v) paraformaldehyde in Dulbecco’s phosphate buffered 
saline (DPBS; GIBCO, Cat#14190) at room temperature for 15 min and then 
permeabilized by 0.25% Triton X-100 in DPBS for 10 minutes prior to blocking by 
1% bovine serum albumin (BSA) in PBST (PBS+0.1% Tween-20) for 1 hour and 
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overnight incubation of primary antibody in 4°C. Primary antibodies used in this 
thesis for immunostaining were: POU5F1 (Santa Cruz, Cat#sc-8628), SSEA4 (from 
DSHB), Tra-1-60 (Chemicon, Cat#MAB4360), TFAP2A (Santa Cruz, Cat#sc-184), 
GATA3 (Santa Cruz, Cat#sc-268), HAND1 (Santa Cruz, Cat#sc-9413X), and 
C-termimal-Phospho-SMAD1/5/8 (Cell Signalling, Cat#9511). After five washes in 
DPBS, cells were incubated with fluorescence conjugated secondary antibodies 
(Molecular Probes, Alexa488 or Alexa568, 1:1000) at room temperature without 
light exposure for 2 hours or at 37°C for 1 hour. Alexa488-labeled secondary 
antibodies were Donkey-anti-goat (Cat#A11055), goat-anti-mouse (Cat#A11001) 
and goat-anti-rabbit (Cat#A11008). Cells which were not incubated with the primary 
antibody but incubated only with the secondary antibody were set as background 
control. After secondary antibody incubation, cells were mounted with mounting 
solution (Santa Cruz Biotechnology, UltraCruzTM, Cat#sc-24941) containing 
4',6-diamidino-2-phenylindole (DAPI). Chamber slides were either examined 
immediately or covered with coverslips for long term storage. Photos were taken 
digitally by a fluorescence microscope (ZEISS Axio Observer D1). 
2.4.4 Fluorescence activated cell sorting (FACs) analysis 
0.25% trypsin/EDTA (GIBCO, Cat#25200) was added to the cells and the tissue 
culture plate was tapped lightly to detach cells from the surface. The trypsin was 
inactivated by the addition of FBS and the cell suspension was pipetted up and down 
to get a single cell suspension. After the cells were pelleted by centrifugation and the 
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supernatant was removed, the cells were washed 3x with DPBS. The cells were then 
fixed with 4% (w/v) paraformaldehyde in DPBS at room temperature for 15 min, 
and then permeabilized by 0.25% Triton X-100 in DPBS for 10 minutes on ice. 
Nonspecific antigens were blocked by incubating the cells with 1% BSA in PBST 
(PBS+0.1% Tween-20) 30 minutes and then incubated with primary antibody at 
room temperature for 1 hour. The cells were washed 3x with DPBS for 5 minutes 
each and incubated with fluorescence conjugated secondary antibodies for 30 
minutes. Cells which were not incubated with the primary antibody but incubated 
with the secondary antibody alone were set as background control. The cells were 
finally washed 3x with DPBS, resuspended in 1ml DPBS, and analyzed on a FACS 
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3.1 Characterization of FGF pathway genes in hESCs 
FGF signaling plays multiple and essential roles in mouse early embryo 
development as reviewed in the introduction section. As evidenced from previous 
expression data sets of hESCs it was clear a number of FGFRs were expressed in 
undifferentiated cells. So I hypothesize that, other than FGF2 for maintaining hESC 
pluripotency, other FGFs may also play critical roles in hESC maintenance and/or 
differentiation. To aid in the selection of FGFs to treat hESCs, I initially 
characterized the FGFR isoforms expressed in hESCs as differential splicing of each 
FGFR leads to differential FGF binding(Ornitz et al., 1996). The mRNA of FGFRs 
were examined by reverse transcription polymerase chain reaction (RT-PCR) and the 
massive parallel signature sequencing (MPSS) data was analyzed (Wei et al., 2005). 
RT-PCR was performed on total RNA isolated from undifferentiated hESCs. 
Forward and reverse PCR primers were designed to exon 7 and exon 10, respectively, 
to distinguish between isoform IIIb and isoform IIIc, which are encoded by exon 8 
and exon 9, respectively, of each FGFR (Figure 3.1B). The PCR products 
electrophoresed on an agarose gel showed positive bands for FGFR1, FGFR2, 
FGFR3 and FGFR4 at the expected size. Because the size difference between 
isoforms IIIb and IIIc is indistinguishable by this separation technique, the bands 
were extracted from the gel and prepared for sequencing (Figure 3.1A). These were 
initially subcloned and subsequent colonies selected for sequencing. Within the 
positive colonies for sequencing, 14/14 Fgfr1 sequences were IIIc; 3/23 and 15/23 
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Fgfr2 sequences were IIIb and IIIc, respectively ( 5/23 of Fgfr2 sequences were 
IIIb+IIIc, which was unknown before); 10/10 Fgfr3 sequences were IIIc; 12/12 Fgfr4 
sequences were IIIc. Analysis of the sequencing results indicated that IIIc was the 
main isoform of FGFR1, 2, 3 and 4 in hESCs. IIIb and IIIc isoforms are considered 
to be expressed mutually exclusively, as FGFR2 IIIb is restricted exclusively to 
epithelial cells, whereas FGFR2 IIIc isoform is generally expressed in mesenchymal 
cells (Cha et al., 2008) ,however, this RT-PCR sequencing approach identified both 
these isoforms for FGFR2 (Figure 3.1B). Whether these isoforms are expressed 
within the same cell or in different cell types within the potentially heterogeneous 
hESC cultures remains unexplored.  
In addition to using RT-PCR for the detection of specific isoforms of FGFR, MPSS 
data previously generated in our group (Wei et al., 2005) was also examined to 
determine specific levels of expression of FGFR, (isoform specificity cannot be 
distinguished by this method) and other genes in the FGF signaling pathway. MPSS 
is a deep sequencing method that generates 20 bp tags 3’ and inclusive of the Dpn II 
restriction site nearest the polyA tail of all mRNAs expressed in a sample. The 
counts of these tags for FGF signaling molecules are shown in Figure 3.1C. In hESC 
of both the pooled WiCell lines and ESI’s HES2, FGFR1, 3, and 4 are expressed, for 
instance in HES2 they have tag counts of  987, 153 and 78 per million transcripts, 
respectively (Figure 3.1C). Unlike mESC where there is almost no expression of 
FGFRs, hESC express significant levels of FGFR1 in addition to lower levels of the 
other FGF receptors. Furthermore, transcripts of proteins downstream of FGFR 
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signaling are present. Different approaches were reported to examine the FGFR 
expression in hESCs, eg. SAGE (Richards et al., 2004), microarray {Carpenter, 2004 
#408}, Q-RT-PCR (Dvorak et al., 2005). In both the MPSS data and the Q-RT-PCR 
data, the expression of FGFRs are FGFR1>FGFR3>FGFR4>FGFR2. 
Summarized from the RT-PCR and MPSS result, FGFR1, FGFR2 and FGFR3 are 
robustly expressed in hESCs and isoform IIIc is the main isoform expressed, 
however, the exact FGFR that FGF2 signals through is yet to be determined. 
Intriguingly, as FGF signaling is most often paracrine in nature, it was evident that 
hESCs also express FGF2 itself. The functional significance of this expression 
remains unknown. 
Based on functional studies in the early mouse embryo, the above FGFR profiling, 
and known FGF-FGFR combination binding specificities (Ornitz et al., 1996; Zhang 
et al., 2006b), FGF4, FGF5 and FGF8 were selected to be used in hESC cultures to 
identify their effects on these cells. However, upon treatment with these FGFs in 
place of the normal FGF2 in hESC media I did not identify any overtly significant 
effects. The treated hESC cultures differentiated towards multiple lineages without 
specific patterns as compared to no FGF controls. As there was no striking effects 
with these FGF treatments, unlike my FGFR inhibitor experiments, I focused the 
remainder of my thesis work on the inhibitor studies.  
 




Figure 3.1 Characterization of FGF Pathway Genes in hESCs. 
(A) Amplicons spanning the IIIb and IIIc domains of FGFR1, FGFR2, FGFR3 and FGFR4 
were detected by RT-PCR of H1 hESCs. (B) The primers designed for detecting the FGFR 
isoforms and the result from sequencing the amplicons in A of indicating the FGFR isoforms 
detected (“+” indicates detected; “-” not detected. (C) MPSS data of FGFRs from ES cells 
and EBs of both human and mouse. Greater than 2 million 20 bp tags were generated by 
MPSS for each sample. The values are expressed as tags per million (tpm). hESWi and hEBWi 
are a pool of the WiCell lines WA01, 07, and 09 which were cultured in feeder-free 
condition, undifferentiated and as 12-day EBs, respectively. hESESI sample was generated 




3.2 Inhibition of FGF signaling pathway in hESC 
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FGF signaling is essential for hESC culture as indicated by the requirement of 
exogenous FGF2 in hESC medium (Adewumi et al., 2007; Amit et al., 2000). FGF2 
was also found to be endogenously expressed by hESC from the MPSS data (Wei et 
al., 2005). When FGF2 is not provided in the hESC medium, hESCs spontaneously 
differentiate into multiple cell lineages with a mixture of different morphologies. To 
determine the specific effects on hESC of FGF signaling, I chose to block FGF 
signaling using a well-characterized specific inhibitor of FGF receptor 1 and 3, 
SU5402 (Grand et al., 2004; Mohammadi et al., 1997).  
My initial FGFR inhibition experiments were designed to begin treatment 24h after 
passaging the hESC culture when cell clusters generated from the collagenase 
digestion during passaging had re-attached to the tissue culture plate. 20µM of 
SU5402 dissolved in vehicle DMSO at a standard concentration, were added into the 
normal hESC medium to inhibit FGF signaling. Control cells were treated with 
vehicle DMSO of the same concentration. Treated cells were harvested 3 days and 7 
days post-treatment, all treatments and controls were performed in biological 
triplicate.   
3.2.1 Morphology of H1 hESC treated with SU5402 
After 7 days of treatment by SU5402, there were significant morphological changes 
between the control H1 hESCs and the treated cells. By the third day of treatment 
with SU5402, cells in the center of colonies started to show differentiated 
morphology. The differentiated cells were flattened single layer cells rather than the 
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stacked 3-dimensional structure of undifferentiated hESC. The differentiated cells 
were not as densely packed as the control cells and appeared to contain greater 
amounts of cytoplasm than did the undifferentiated hESC which are known to have a 
low cytoplasm to nucleus ratio (Figure 3.2). Though it was not clear from the 
morphology what cell type these resembled, the morphological change did suggest 
the FGFR inhibition was causing the hESCs to differentiate. 
 
Figure 3.2 The cell morphology of H1 hESC treated with FGFR inhibitor SU5402.  
H1 hESC cultures were either untreated (left panel, control) or treated for 3 days (middle 
panel) or 7 days (right panel) with FGFR inhibitor SU5402 (20 uM).   
 
3.2.2 mRNA expression profiling of H1 hESC treated with SU5402 
Initially I used a panel of TaqMan gene expression assays representing at least two 
genes from each possible cell lineage a hESC could differentiate to and analyzed by 
real time PCR, the SU5402 treated samples. This gave the first evidence that FGFR 
inhibition in hESC leads to differentiation along the trophoblast lineage as both 
CDX2 and CGA (encoding the alpha subunit of the pregnancy hormone hCG) were 
significantly up-regulated whereas none of the other genes representative of the 
   
 
85
different cellular lineages were up-regulated. To gain a comprehensive 
understanding of the gene expression changes that were occurring I next analyzed all 
three biological replicates from the undifferentiated hESCs and the 3 and 7 day 
SU5402 treated samples by Illumina BeadArrays which contain approximately 
24,000 genetic features. The analysis of these data provided convincing evidence 
that the treated cells were differentiating along the trophoblast lineage. 
As shown in Figure 3.7, the mRNA expression level of the hESC marker NANOG 
was down-regulated after 7 days of treatment by SU5402 to a much lower level than 
found in undifferentiated cells. The mRNA expression levels of other hESC markers, 
such as GDF3, UTF1, POU5F1 and SOX2 remained relatively unchanged from the 
control. The relatively little change in all these pluripotent markers was surprising 
considering the significant up-regulation of many trophoblast markers (see below). 
After only 3 days of SU5402 treatment there were numerous trophoblast markers, 
particularly transcription factors, which were significantly up-regulated. These 
included DLX3, TFAP2A, HAND1, GATA3, GATA2, MSX2, IGFBP3, ID2, MSX1, 
CDX2, BMP4, VEGF and TFAP2C (Figure 3.7). The most striking up-regulation 
were the 3 transcription factors TFAP2A, DLX5, and HAND1. Although not 
up-regulated at 3 days of treatment there were numerous other trophoblast markers 
such as CGA, GCM1, ERVWE1, PGF, IGF2, KRT7, EGFR, HSD17B1, HLA-G, 
KRT8 and KRT18, that were significantly up-regulated after 7 days of treatment by 
SU5402. The two most significantly up-regulated genes falling in this category were 
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CGA and GCM1. The significant up-regulation of all these known trophoblast 
markers suggested the SU5402 treated cells differentiated along a trophoblast 
lineage although this did not appear to coincide with robust down-regulation of 
pluripotency markers. 
To get a truly unbiased view of placental expression rather than just relying on 
known placental genes I next compared the top 100 up-regulated genes by 7 days of 
SU5402 to a placental-specificity score based on information in the UniGene 
database (Wheeler et al., 2003) of expressed sequence tags (ESTs). Of the 6,681,838 
human ESTs in Build#214 of these database, 283,990 are derived from cDNA 
libraries generated from placental tissue. The placental-specificity score that I 
developed was calculated by comparing the number of ESTs for a specific gene 
within placental libraries to the total number of ESTs for that gene in the entire 
UniGene database. The combined placental-specificity score for GAPDH-ACTB, 
two classical housekeeping/endogenous control genes, was 3.6%, that is to say 3.6% 
of all GAPDH and ACTB ESTs come from placental libraries. I defined 
placental-enriched genes to be at least 2.5-fold above the average of this 
GAPDH-ACTB placental-specificity score (i.e. above 9%). 
Of the top 100 up-regulated genes after 7 days of continuous treatment with SU5402, 
a striking 43 were identified as placental-enriched (Figure 3.3). Comparing the same 
gene list to lung (338,067 total ESTs) and intestine (235,391 total ESTs), two other 
organs with a similar number of total ESTs to that of placenta, indicated 12 of these 
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100 genes were lung-enriched and 8 were intestine-enriched (data not shown). 
Highly enriched placental genes, defined as those genes with 20% or more of ESTs 
derived from the placenta, found on this top 100 list include VGLL1 (a co-activator 
of TEAD4 (Vaudin et al., 1999)), GCM1, HSD3B1, CGA, PGF, CCBP2, GATA2, 
DLX3, MSX2, TFAP2A, PPARG. Note that the placental-specificity score likely is an 
underestimate as ESTs generated from libraries of mixed tissues (including placenta) 
are excluded. Besides the striking enrichment of many known trophoblast 
transcription factors and the classic trophoblast marker HCG encoding the alpha 
peptide of chorionic gonadotropin (aka. the pregnancy hormone), also included are 
HSD3B1 and CCBP2, both known to be functionally important in maintaining 
pregnancy. CCBP2 protects against spontaneous abortions by systemic inflammation 
by virtue of its ability to degrade inflammatory CC chemokines (Martinez de la 
Torre et al., 2007). HSD3B1, along with CYP11A1/P450scc, is required for the 
biosynthesis of progesterone and thus is essential for the maintenance of pregnancy. 
CYP11A1, although falling outside this top 100 list (it is 128th most up-regulated) is 
also induced by SU5402. 
From the global gene expression profiling there was no evidence for the 
up-regulation by SU5402 treatment of marker genes of ectoderm (SOX1, PAX6, 
GFAP and NEUROD1), mesoderm (T, PECAM1, MYF5, and MYOD1), endoderm 
(SOX17, GATA4) or germ cells (SYCP3) . Thus, from the global gene expression 
profiling it is evident that SU5402, a specific inhibitor of FGFR signaling, results in 
hESC differentiation predominantly, if not solely, down the trophoblast lineage.   




Figure 3.3 The 43 placental-enriched genes from the top 100 up-regulated genes of H1 
hESC treated with SU5402 for 7 days.  
This graph plots a measure of placental-specificity of each gene based on the EST NCBI 
data base which contains 274,038 ESTs generated from human placenta. Graphed is the 
percentage of placental ESTs/total ESTs for each gene (see text for details). As a reference 
ACTB and GAPDH (not shown) have 3 and 4% of their ESTs, respectively, generated from 
the placenta.  
 
3.2.3 Protein expression of H1 hESC treated with SU5402 
Although from the global gene expression studies there did not appear to be a 
significant down-regulation in the levels of pluripotent gene mRNAs, there was 
strong evidence that the cells were differentiating based on morphological changes 
as well as the vast up-regulation of trophoblast markers. For this reason I wanted to 
determine if the protein levels for the pluripotent-specific transcription factor 
POU5F1, known to be essential for the pluripotent state, was altered at all. For this 
H1 hESCs were treated with SU5402 for 6 days and the protein expression of 
POU5F1 was examined by indirect immunofluorescence staining. Consistent with 
the morphological observation of differentiation but strikingly different to mRNA 
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levels, POU5F1 was depleted in SU5402 treated cells. The depletion of POU5F1 
protein while maintaining its mRNA may imply that the translation process is being 
targeted in the induced differentiation process and no translation could take place. 
The post-translational regulation may be mediated by RNA binding protein, 
microRNAs (Xu et al., 2009) and/or RNA interference (Ding et al., 2009). The 
positive control undifferentiated hESCs showed abundant nuclear-localized staining 
(Figure 3.4). This result provides further evidence that SU5402 treated hESCs lost 
their pluripotency in the differentiation process but also suggests that the 
down-regulation of OCT4 protein precedes that of its mRNA invoking 
post-transcriptional control of the down-regulation of POU5F1. 
 
Figure 3.4 The immunostaining of pluripotency marker POU5F1 in H1 hESC.  
The untreated H1 hESC (left panel) and the H1 hESC treated with SU5402 for 6 days (right 
panel). Nuclei were stained with DAPI. Images were collected from a confocal microscope. 
3.3 BMP4 treatment on H1 
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BMP4 has previously been reported to induce trophoblast cell differentiation in 
human ES cells (Xu et al., 2002b). As treatment of hESCs with the FGFR inhibitor 
SU5402 clearly also directed the cells to differentiate along the trophoblast lineage 
(as described above), I was next interested to compare the similarities between these 
two treatments. As differentiation was morphologically evident by 3 days of 
treatment, this was chosen as the first time point for comparison, and a second time 
point at 7 days. H1 hESCs were treated with 100ng/ml of BMP4 (as in (Xu et al., 
2002b)) on the next day after passage. Treated cells were harvested after 3 days and 
7 days of treatment. 
3.3.1 Morphology of H1 hESC treated with BMP4 
BMP4 treated cells began showing morphological signs of differentiation after two 
days of treatment, and overtly differentiated morphology by the third day (Figure 
3.5A). Highly similar to SU5402-treated hESC, the differentiated cells were 
flattened single layer cells rather than the stacking 3-dimensional structure of 
undifferentiated hESC. The differentiated cells were sparsely neighboring each other 
with greater cytoplasmic/nucleus ratios compared to that of the undifferentiated 
hESC. One notable difference between the SU5402 versus the BMP4 treated hESCs, 
is that the cells at the edge of BMP4-treated colonies showed the first signs of 
differentiation whereas differentiated cells first appeared evident in the middle of 
SU5402 treated colonies. By seven days, hESC colonies treated with SU5402 or 
BMP4 both show fully differentiated morphologies (Figure 3.5A).  
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3.3.2 mRNA expression profiling of H1 hESC treated with BMP4 
To determine the underlying molecular changes occurring upon BMP4 treatment I 
again used Illumina Bead Arrays to generate global gene expression profiling data 
for the 3 and 7 day treated hESC cultures. This indicated that the hESC markers 
NANOG and GDF3 were down-regulated significantly compared to their hESC 
levels after 3 days of treatment by BMP4 (Figure 3.7). Similar to the SU5402 
treatment mRNA levels of other hESC markers, such as UTF1, POU5F1 and SOX2 
changed little over the 7 days of treatment. 
The up-regulation of trophoblast-specific genes upon BMP4 treatment of hESC, as 
characterized previously (Xu et al., 2002b), was quite evident. Trophoblast markers 
DLX3, TFAP2A, HAND1, GATA3, GATA2, MSX2, IGFBP3, ID2, MSX1, CDX2, 
BMP4 and FN1 were all significantly up-regulated after 3 days of treatment. Similar 
to the SU5402 treatment TFAP2A, DLX5, and HAND1 were the three most 
up-regulated genes with fold increases of 58, 29, and 58 respectively. Other 
trophoblast markers CGA, GCM1, ERVWE1, PGF, IGF2, KRT7 and EGFR were 
only significantly up-regulated after 7 days of treatment by BMP4. Again, similar to 
the SU5402 treatment (though significantly lower) CGA and GCM1 were the two 
most up-regulated at this stage at 73 and 8 fold above their levels in the 
undifferentiated hESC and 3 day treated BMP4 cells. 
Markers of ectoderm (SOX1, PAX6, GFAP and NEUROD1), mesoderm (T, 
PECAM1, MYF5, and MYOD1), endoderm (SOX17, GATA4) and germ cells (SYCP3) 
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were not detected in the control hESC or the treated cells. 
3.3.3 Comparison between hESCs treated with BMP4 versus SU5402 
Both the BMP4 and SU5402 treated hESCs differentiate towards the trophoblast 
lineage, as identified by morphology and gene expression profiling. Indeed some of 
the most significantly up-regulated genes are shared between the two treatments. To 
further explore to what extent this similarity existed I next compared, as shown in 
the Venn diagram (Figure 3.5B), the top 100 up-regulated genes found in each of the 
two 3-day treatments. Also included in this comparison were all the genes identified 
as up-regulated greater than 2 fold in the 3 day BMP4 treatment to see to what extent  
the top 100 up-regulated genes upon SU5402 treatment overlapped with any gene 
up-regulated in the BMP4 treatment. From the comparison between the top 100 
genes for either treatment there were 38 genes that were shared. This included well 
known trophoblast transcription factors such as DLX3, DLX5, GATA2, GATA3, 
HAND1, ID2, MSX1, MSX2 and TFAP2A. 
Strikingly, 69 of the top 100 up-regulated genes upon SU5402 treatment were also 
up-regulated at least 2-fold in the BMP4 treatment. The extent to which global gene 
expression changes overlap between these two quite different treatments is 
remarkable particularly considering the gene expression comparisons were 
performed 3 days after the initial treatments along a developmental continuum. This 
would provide ample time for secondary and tertiary events downstream of the 
initial signal alterations of the original treatments, to occur. This indicated that at 
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some point after the initial activation of BMP and inhibition of FGF signaling there 
is a strong convergence on to the trophoblast lineage.  
 
Figure 3.5 H1 hESC treated with BMP4 
(A) A comparison of cell morphologies between undifferentiated H1 hESC (left panel) and 
these cells treated with 100 ng/ml BMP4 for 3 days (middle panel) and for 7 days (right 
panel). (B) A Venn diagram comparing genes up-regulated by BMP4 treatment and SU5402 
treatment of 3 days as detected by gene expression bead arrays. A sample of some of the 
transcription factors that are up-regulated in both treatments are shown.  
 
 
3.4 Combined treatment of FGFR inhibitor and BMP4 on hESC 
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The high similarities in morphology and gene regulation between BMP4 and 
SU5402 treated hESC strongly suggests that FGF and BMP signaling have some 
crosstalk in inducing trophoblast differentiation from hESC. BMP signaling is 
transduced to the nucleus by the C-terminal phosphorylation of SMAD1/5/8. In a 
recent report, FGF signaling was shown to antagonize BMP signaling by enabling 
phosphorylation in the linker region of SMAD1 causing ubiquitination and 
subsequent degradation of SMAD1 (Sapkota et al., 2007). Though this was not 
characterized in hESCs it could perhaps at least partially explain why both 
treatments produced these highly similar results. FGF2 required in maintaining 
hESC in the undifferentiated state may work by blocking differentiation induced by 
Smad1/5/8 activation by destabilizing this BMP-inducible transcription factor. 
To begin to address this possibility we reasoned that a combination of the BMP4 and 
SU5402 treatment may strengthen the trophoblast differentiation by providing more 
Smad1/5/8, stabilized through SU5402, to transmit the exogenous BMP4 signal. 
Thus I next treated hESCs with 100ng/ml BMP4 together with 20µM SU5402, 
termed the BS treatment, and analyzed its effect on hESC morphology, global gene 
expression profile, and the protein expression of specific trophoblast factors. In 
addition, to determine the activation status and sub-cellular localization of activated 
SMAD1/5/8 between the different BMP4, SU5402 and BS treatments, I used a 
C-terminal phospho-specific antibody of SMAD1/5/8 for immunostaining. In these 
experiments the treatment started 24 hours after the last passage and cells were 
harvested on the 3rd day and the 7th day of the treatment, and with all samples run in 
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biological triplicate.  
3.4.1 Morphology of H1 hESC treated with BS 
As hypothesized, the BS treatment accelerated the differentiation: on the 3rd day of 
BS treatment, the H1 hESCs showed more obvious differentiation morphology than 
the BMP4 and SU5402 treatments alone. On the 7th day of BS treatment, almost all 
of the H1 hESCs were differentiated. Changes in morphology were first noted in the 
center of colonies in SU5402 treated H1 hESCs and started from the edge of 
colonies in BMP4 treated H1 hESCs, while in BS treated H1 hESCs, the 
differentiation occurred all over the colonies, showing the combination effect of the 
two single treatments (Figure 3.6). 
 
Figure 3.6 The cell morphology of H1 hESC treated with BMP4+SU5402 (BS).  
Bright field images of untreated H1 hESCs (left panel) and hESCs treated for 3 days (middle 
panel) and 7 days (right panel) with a combination of 100 ng/ml BMP4 and 20 uM SU5402. 
. 
 
3.4.2 Global gene expression profiling of H1 hESC treated with BS 
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Consistent with the increased rate of morphological change, there were substantial 
changes identified by global gene expression profiling. Most strikingly, as this was 
not identified in either of the single treatments, was the robust down-regulation of 
hESC markers in the combined BS compared to either the BMP4 or SU5402 
treatments (Figure 3.7). NANOG levels dropped to virtually nil within 3 days of 
combined treatment, the Illumina raw signal was 5.00 at 3 days compared to 1,910 in 
the undifferentiated hESC. POU5F1 also declined drastically although substantial 
levels were still present after 3 days of differentiation. (Note, at this point it became 
clear the SOX2 probe on this array was not working based on my and other people’s 
data). The down-regulation of these pluripotency markers was in stark contrast to 
either of the single treatments with the combined treatment leading to much greater 
down-regulation in the 3 day sample compared to that seen even in the 7 day 
samples of the single treatments. 
Along with this robust down-regulation of pluripotency markers the combined 
treatment drastically increased the levels of trophoblast markers (Figure 3.7). Many 
of the same trophoblast markers identified as up-regulated in the two single 
treatments at 3 days were also up-regulated in the combined BS treatment at 3 days 
but to a much greater level, eg. TFAP2A, HAND1, GATA3, CDX2, and DLX5. In 
addition, there were genes identified as up-regulated in the two single treatments 
only after 7 days of treatment that were already abundantly up-regulated in the 
combined treatment by 3 days, for instance CGA and GCM1 (more listed in Figure 
3.7). Furthermore, genes that were not identified as up-regulated in either the 3 or 7 
   
 
97
day single treatments were now identified as up-regulated by 7 days of the combined 
treatment. One gene of particular interest in this category is CGB, the beta peptide of 
hCG (the alpha peptide being CGA). The expression of CGB is known to be initiated 
later than CGA in trophoblast development. These data suggested that not only was 
the combined treatment increasing the trophoblast gene expression over the single 
treatments but that the combined treatment lead to the hESC cells progressing further 
along the trophoblast differentiation program. To indentify the cell types of BS and 
SU5402 treatment, markers of trophoblast sub-population were used to exam by 
immunostaining, CSH1 for syncytiotrophoblast and HLA-G for extravillous 
trophoblast respectively (Robins et al., 2007), however, no positive result was 
achieved. 
Of note also was the up-regulation of genes involved in immune suppression in the 
combined treatment, presumably in preparation for the implanting trophoblast to 
evade the damaging effects of the maternal immune system. Immune related genes 
HLA-A and HLA-B were down-regulated after 7 days treatment of BS consistent with 
previous reports that they were not expressed in the trophoblast, this in contrast to 
the up-regulation of HLA-G and HLA-E which were both reported to be expressed in 
the trophoblast (Hunt et al., 2005; Kovats et al., 1990).  
With regards to the closely related SMADs 1, 5, and 8, there are significant 
differences between the mRNA levels of these BMP4 downstream signal transducers. 
Based on the Illumina bead array data there is very little detection of SMAD1 (raw 
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signal 30.67), no detection of SMAD8 (raw signal 2.02) but very abundant detection 
of SMAD5 (raw signal 3,385) in the undifferentiated hESC. SMAD5 levels remain 
high throughout the differentiation, SMAD1 levels are unchanged, while SMAD8 
levels increase over the differentiation time course. From this I conclude that 
SMAD5 is the likely molecule that transduces the BMP4 signal in hESC. The 
antibody used for detecting phosphorylated-SMAD5 in experiments described 
further on recognize all three of these phosphorylated/activated R-SMADs but was 
















Figure 3.7 Selected genes from global gene expression profiling of hESC treated with 
BMP4, SU5402 and BMP4+SU5402 
Color spectrum represents fold change of gene expression level in treated hESC compared to 
untreated hESC. Gene expression levels were determined by Illumina BeadArrays with 3 
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3.4.3 Protein expression of H1 hESC treated with BS 
To confirm that the up-regulation of trophoblast markers at the mRNA level also 
correlated with an increase in protein expression, hESCs induced to differentiate by 
BS treatment into the trophoblast lineage were analyzed for expression of 
trophoblast related proteins. In addition, I analyzed the expression of activated 
SMAD5 to determine the similarities in responsiveness between the different 
treatments.  
3.4.3.1 Immunostaining of H1 hESC treated with BS 
To begin to address whether the mRNA levels detected in the bead array 
experiments correlate with protein levels I performed indirect immunofluorescence 
microscopy. For these experiments H1 hESCs were treated with BMP4+SU5402 for 
8 hours, 1 day and 5 days. The 5 day treatments began the day after passage. The 8 
hours and 1 day treatments began on the 3rd day after passage.  
3.4.3.1.1 Immunostaining of trophoblast related transcription factors 
From the Illumina bead array data the three transcription factors TFAP2A, GATA3, 
and HAND1, which are all known to play roles in the regulation of the trophoblast 
gene expression program, were highly up-regulated upon combined BS treatment. 
The analysis of the raw expression signals for each from these data indicated 
virtually nil expression for all three in undifferentiated hESC. The absence of 
expression in undifferentiated hESC was further supported by indirect 
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immunofluorescence microscopy using primary antibodies directed against these 
transcription factors (Figure 3.8A). In contrast, hESC cells differentiated for 5 days 
with the combined BS treatment showed robust and nuclear-localized staining of all 
three transcription factors. Furthermore, this staining appeared to be uniform for all 
three transcription factors across all cells within the culture as all cells staining 
positive with the nuclear dye DAPI were expressing these factors (Figure 3.8A). 
Thus I concluded from this that the mRNA levels of these factors as detected by the 
bead arrays corresponded closely with the protein levels and that the differentiation 
program appeared to be uniform. 
3.4.3.1.2 Immunostaining of C-Terminal-Phosphorylated-SMAD5 
An antibody specific to the C-terminal-phosphorylated-SMAD5 (and SMAD 1 & 8) 
detects the activated form of this transcription factor. Although this phosphorylation 
is thought to occur in the cytoplasm, once phosphorylated the SMAD quickly 
translocates into the nucleus. In undifferentiated H1 hESCs there was little evidence 
that SMAD5 was activated as there was virtually no positive immunostaining with 
this antibody whereas in the H1 hESCs treated with BMP4+SU5402 for 5 days there 
was robust and nuclear localized staining (Figure 3.8A) as would be expected with 
100 ng/ml pf BMP4 in the culture media. The activation of SMAD proteins is 
thought to be a rapid event direcetly followed by BMP activation whether 
endogenously or exogeneouly, thus I next looked at earlier time points of 
differentiation for SMAD5 activation. Indeed, the C-terminal-phosphorylated 
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SMAD5 was also detected and nuclear localized in H1 hESCs treated with BS for 
1day and as little as 8 hours (Figure 3.9). As I have hypothesized earlier that the 
similarities in the single FGF inhibition and BMP4 treatments is a result of a 
convergence through SMAD5 signaling I also analyzed activated SMAD5 in such 
treated cell. Both single treatments for 8 hours and 1 day result in activated and 
nuclear localized SMAD5, suggesting the these treatments do at least partially 
converge through the activation of SMAD5.  
3.4.3.2 Western blot of H1 hESC treated with BS 
In further characterization of the trophoblast phenotype found in BS-induced hESC 
cultures I performed Western blots on H1 cells induced to differentiate for 7 days. 
Compared to undifferentiated hESCs the well known trophoblast markers ID2 and 
KRT18 were up-regulated (Figure 3.8B). 
3.4.3.3 BS-treated hESC secrete hCG 
The classical marker of pregnancy is hCG which is secreted from the trophoblast. 
Measuring for hCG secretion in the original hESC paper (Thomson et al., 1998) was 
in part what was used to define hESCs ability to give rise to the trophoblast lineage. 
It is hCG that is measured in the widely used pregnancy test sticks. Thus to measure 
hCG levels in BS-induced hESC differentiation culture I purchased a pregnancy test 
kit from a local pharmacy and applied media from 5 day differentiation cultures to 
this and compared it to media from undifferentiated hESC cultures. The pregnancy 
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test stick only showed one control band from the undifferentiated media whereas two 
bands appeared from the differentiated sample, indicating that by 5 days of BS 
treatment the cells are actively producing the pregnancy hormone hCG (Figure 
3.8C). 
 
Figure 3.8 Protein detection in BS treated H1 hESC 
(A) The immunostaining of trophoblast-related transcription factors TFAP2A, GATA3 and 
HAND1 and C-terminal phosphorylated SMAD5. Two panels are shown for each staining, 
one for the specific protein of interest and the second for the corresponding DAPI nuclear 
dye. (B) The protein expression of trophoblast markers ID2 and KRT18 were compared 
between undifferentiated H1 hESC and cells treated with BS for 7 days by western blot. (C) 
Media collected from undifferentiated hESC (control) and cells treated with 100ng/ml 
BMP4 and 20 uM SU5402 (BS) were analyzed for the detection of the trophoblast hormone 
hCG by a commercially available hCG detection kit. The arrowhead indicates a positive 
band.  




Figure 3.9 Immunostaining for activated SMAD5 in hESC treated with S, BMP4 and 
BS for short times 
The immunostaining of C-terminal phosphorylated SMAD5 in H1 hESC treated with S, 
BMP4and BS for 8 hours (upper row) and 1 day (lower row).  
3.4.4 BMP signaling is involved in the differentiation induced by FGF inhibition 
The combined treatment of BMP4 and SU5402 showed dramatic amplification and 
speed of trophoblast induction from undifferentiated hESC cultures compared to 
single treatments of either SU5402 or BMP4. I next wanted to see what the 
relationship between the two signaling pathways was in regard to inducing this 
differentiation. To this end I employed the BMP antagonist NOGGIN which inhibits 
the initiation of BMP signaling through its receptor upstream of SMADs. Using a 
concentration of 500ng/ml NOGGIN (Wang et al., 2005; Xu et al., 2005b) I set up 
an experiment where I cultured hESCs in 6 different conditions: untreated hESCs 
(ctrl) and H1 hESCs treated with BMP4 (B), BMP4+SU5402 (BS), NOGGIN (N), 
NOGGIN+SU5402 (NS) and SU5402 (S). All cultures contained FGF2 and cultures 
were analyzed by morphology and gene expression after 2 days of treatment. 




There were no morphological differences between any of the treated hESC cultures 
to that of the untreated control hESCs (Figure 3.10), that is to say they all looked like 
good undifferentiated hESC colonies. This was not surprising considering the 
treatment was carried out for only 2 days; the earliest previous morphological signs 
of differentiation was not seen until the 3rd day of treatment. 
 
Figure 3.10 Cell images of H1 hESC treated with BMP4 (B), BMP4+SU5402 (BS), 
NOGGIN (N), NOGGIN+SU5402 (NS), SU5402 (S), and untreated (control). 
3.4.4.2 mRNA expression profiling 
Gene expression levels for three pluripotency markers and ten trophoblast markers 
were analyzed by Taqman real time PCR. Outside of the context of the NOGGIN 
experiments, for the B, S, and BS treatments this gave independent verification 
(Figure 3.11A) of the earlier array-based expression analysis. In all but the control 
and NOGGIN alone treatments trophoblast markers were up-regulated and most 
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significantly in the combined BS treatment. Noggin alone reduced the expression of 
a number of trophoblast markers suggesting that BMPs within the untreated culture 
system, either derived from the MEF conditioned media or from the hESC 
themselves, do contribute to the up-regulation of trophoblast genes in hESC cultures 
without Noggin. Indeed, there are previous reports of Noggin, combined with FGF2, 
improving the undifferentiated state of hESC cultures (Wang et al., 2005; Xu et al., 
2005b). 
The key comparison in this experiment was the comparison of the SU5402 alone 
treatment to that of SU5402 and Noggin combined. With regards to the selected 
pluripotency markers, there was no reduction in the down-regulation of these in the 
NS treatment compared to S alone (Figure 3.11A). This would suggest that the 
modest down-regulation seen in the S alone treatment is not mediated through any 
effects of the BMP signaling pathway. 
In contrast, the up-regulation of trophoblast markers seen in the S alone treatment 
was substantially reduced when S was combined with NOGGIN (Figure 3.11B). 
Although the up-regulation of some trophoblast markers was virtually abolished in 
the combined NS such as MSX1 and ID2, other markers were still up-regulated 
significantly. For instance, though the up-regulation of DLX3, GATA2, and TFAP2A 
in the SU5402 alone treatment were all significantly reduced in the NS treatment 
there was still an approximately 10-fold increase in expression of these trophoblast 
transcription factors. Tthese results clearly show that, on one hand, BMP4 signaling 
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is involved in the differentiation induced by FGFR inhibition, likely through the 
stabilization of SMAD5; on the other hand, the entire SU5402 effect is not fully 
mediated through the BMP signaling pathway,. 
 
Figure 3.11 Simultaneous inhibition of BMP and FGF signaling in H1 hESC 
Taqman real time PCR expression profiling of selected genes after 2 days of various 
treatments (A) pluripotency markers. (B) trophoblast related markers. The Ct value is that 
detected in the untreated hESC, the sample that all others are relative to. The Y-axis shows 
the fold changes compared to the control on log10 scale. B - BMP4, BS - BMP4+SU5402, N 
- NOGGIN, NS - NOGGIN+SU5402, S - SU5402, untreated - ctrl 
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3.5 Short time treatment of BMP4, SU5402 and BMP4+SU5402 on H1 hESC 
Clearly, the data presented up to here shows that individual treatments of either 
SU5402 or BMP4 direct hESC to differentiate towards trophoblast lineage and that 
by 3 days of treatment the transcriptional response is highly similar between the two. 
I have also indicated that some of this similarity may be a result of convergence 
through SMAD5. That said, the NOGGIN experiments above highlight that FGFR 
inhibition does not solely work through SMAD5 stabilization in directing hESC 
towards the trophoblast lineage. 
To better understand the molecular events leading to the convergence onto this 3 day 
expression pattern I next spent considerable time generating global gene expression 
data sets from comprehensive time courses of differentiation of shorter periods of 
BMP4, SU5402, and BMP4+SU5402 treatments of H1 hESC. The time course 
experiment for the SU5402 treatment was actually done much earlier than the later 
two time courses and used an earlier version (v1) of the Illumina bead array. The 
time points for this experiment were 0, 2, 8, 16, 24, and 48 hours and performed in 
biological quadruplicate. For the BMP4 alone and the SU5402+BMP4 time courses 
the version 2 (v2) bead arrays were used. Time points for BMP4 alone were 0, 1, 2, 
4, 8, 16, 24, 48, and 72 hours and done in biological triplicate and for 
SU5402+BMP4 were 0, 1, 2, 4, 8, 16, 24, 40, 48, 72, and 96 hours and done in 
biological quadruplicate. Below I only highlight some features of these data but the 
entire data set remains an actively mined resource in the Robson lab. 
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3.5.1 Early Response Genes 
An overall view of these expression time course data sets indicate substantial gene 
expression changes in all treatments at very early times in addition to subsequent 
later waves of expression for different sets of genes. Here I focus on the earliest 
events to gain insight into the direct actions of SU5402 inhibition and BMP4 
signaling. Shown in Figure 3.12 are the top twenty differentially expressed genes 
between the undifferentiated hESC and those induced to differentiate for 8h with 
SU5402, BMP4, and the SU5402+BMP4 combination. It includes the top twenty up- 
and down-regulated genes. Immediately apparent is the much more dramatic 
up-regulation of genes from the BMP4 treatment as compared to the SU5402 
treatment, the highest up-regulation in the BMP4 is 36.6-fold increase whereas in the 
SU5402 treatment it is only 5.78-fold, this would only rank as the 18th most 
up-regulated gene in the BMP4 treatment. 
Another feature that is immediately apparent in the BMP4 up-regulated list is the 
abundance of trophoblast transcription factors. TFAP2A, GATA2, HAND1, MSX2, 
ID2, and GATA3 are all in the top twenty up-regulated genes by BMP4, CDX2 falls 
just outside the top twenty up-regulated list, it is 30th with a fold-increase over the 
undifferentiated hESC of 3.8. Many of these genes are immediately responsive being 
activated within 1 to 2 hours of BMP4 induction (see heatmap in Figure 3.12) 
suggesting these are all direct targets of BMP4-acitivated SMAD5. In contrast, there 
is a complete absence of these trophoblast transcription factors in the SU5402 
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up-regulated list indicating that the influence of SU5402 on SMAD signaling is not 
yet apparent within 8h of treatment. 
Opposite to that seen for the up-regulated genes, in the top twenty down-regulated 
genes it is apparent that the SU5402 treatment is a much stronger inducer of 
down-regulation than BMP4 is. The top repressed gene in the BMP4 treatment 
would only rank as the 27th most down-regulated gene in the SU5402 treated cells. 
Of note are the two most down-regulated genes in the SU5402 treatment, EGR1 and 
DUSP6, as both are known to be activated by FGF signaling (Ekerot et al., 2008; 
Midgley and Khachigian, 2004; Santiago et al., 1999) thus validating this list in its 
ability to detect genes responsive to FGFR inhibition. 




Figure 3.12 Top 20 early expression changes.  
Heatmaps generated within GeneSpring from the Illumina bead array time course data for 
H1 hESC treated with BMP4, SU5402 and BMP4+SU5402 as indicated. The top 20 genes 
based on fold difference from 0h vs 8h are represented for up-regulated (top maps) and 
down-regulated (bottom maps) genes. Coloring: blue – low expression; red – high 
expression.  
 
Clearly, the comparison of these top twenty lists was indicating very little similarity 
in the hESC’s response between SU5402 and BMP4 treatments. To provide a more 
global view of this I next compared the lists of all genes up-regulated and 
down-regulated 2-fold or greater between the undifferentiated hESC and the cells 
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induced to differentiate for 8h with the three treatments (Figure 3.13). The total 
number of genes for SU5402, BMP4, and the combination SU5402+BMP4 that were 
down-regulated were 189, 137, and 602, respectively, and up-regulated 73, 167, and 
571, respectively. A comparison of these numbers clearly shows the amplification of 
changes when the two treatments are used in combination. Also highlighted by these 
Venn diagrams  are the extreme lack of similarity between early responsive genes 
between the SU5402 and BMP4 treatments, only 6 genes overlap (3 if you include 
the combined treatment) between the down-regulated genes and only 9 (8 if you 
include the combined treatment) overlap. 
This would strongly argue that the two treatments are initially independent of one 
another with little overlap and that it is subsequent events later than 8h that lead to 
the convergence of expression by 3 days. That said, the genes that do overlap all 
three treatments (highlighted in Figure 3.13) perhaps are playing a role in this 
downstream convergence. Of the three genes down-regulated DUSP6 stands out, this 
is known to be relatively specific to both human and mouse ES cells and considered 
a negative regulator of FGF signaling. Of the eight up-regulated genes (actually six 
taking into account probe redundancy) GRHL3 stands out, recent unpublished data 
from the Robson lab indicate close homologs of this over-expressed in mouse ES 
cells can drive trophoblast gene expression. 
 




Figure 3.13 Global early expression change comparisons.  
Venn diagrams representing all genes down-regulated (left panel) and up-regulated (right 
pane) by 2-fold or greater (0h vs 8h) in SU5402, BMP4, and SU5402+BMP4 treated H1 
hESC. This generated from the same data set as that in Fig3.16. 
 
3.5.2 Response of BMP direct target genes in SU5402 treatment 
From these bead array experiments detecting early time point gene expression it is 
possible to catalogue a list of presumably direct target genes of BMP4 in hESCs. 
One reason I wanted to identify these genes is so that I may see how these genes 
respond in the SU5402 treatment. I classified as direct targets for this sake any gene 
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that was up 4-fold or greater by 4h of BMP4 treatment. This list consisted of 37 
genes many of which were known direct targets of BMP signaling as identified in 
other systems, genes such as IDs 1 thru 4 (Lopez-Rovira et al., 2002), DLX5 
(Miyama et al., 1999), MSX2, GATA2 and GATA3 (Karaulanov et al., 2004). So 
many known direct targets within this list validates its quality. 
I then analyzed the SU5402 treated hESC time course data for the expression of 
these 37 genes (Figure 3.14), note though that a few of these genes were not on the 
v1 array used for the SU5402 analysis. Many of them are indeed up-regulated over 
this 48h time course but the up-regulation is not immediate (Figure 3.14A). To see 
when the greatest change in expression occurred I used principal component analysis 
within GeneSpring (Figure 3.14B) which clearly shows the greatest change in 
expression for this set of genes as a whole is in the 8h to 16h transition suggesting 
that at this point SMAD5 activation/nuclear localization is occurring. 




Figure 3.14 Response of BMP4 Target Genes in Single SU5402 Treatment.  
 
(A) Expression profile in SU5402 differentiation time course of H1 hESC of genes identified 
as up-regulated 4-fold or greater within 4h of BMP4 induction. Red – high expression, blue 
– low expression. (B) Principal component analysis (PCA) of the 35 genes in A. PC1 has an 
explained variance of 55.62%, PC2 of 17.73%, and PC3 of 10.8%. Sample time points are 
indicated and the greatest change between any two samples (8h to 16h) is indicated with 
dashed arrow. 
 
3.6.3 SU5402 Does Stabilize SMAD5 
From the above analysis it still was not clear if SU5402 was working through the 
stabilization of SMAD5 at all as in the single SU5402 treatments the up-regulation 
of SMAD target genes was delayed. Thus I designed another set of experiments 
where I would follow up an initial 6h treatment of either BMP4 or SU5402 with the 
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combination SU5402+BMP4 treatment. This idea originated with the analysis of the 
array data which suggested that although the initial up-regulation of BMP target 
genes were equivalent in the BMP alone and the combined treatment, after 8 to 16h 
the levels of BMP target transcripts continued to rise in the combination treatment 
but leveled off in the BMP alone treatment. 
As shown in Figure 3.15, all four BMP4 target genes analyzed (DLX5, ID2, GATA2 
and MSX2) show an immediate response to BMP but not to SU5402 alone. 
Interestingly however, for three of the four genes adding SU5402 to the media (and 
maintaining BMP4 levels) after 6h of BMP4 treatment led to a further up-regulation 
of BMP4 target genes, an up-regulation not seen in the cultures that were 
continuously treated with BMP4 alone. This would argue that indeed SU5402 is able 
to directly influence the activation of BMP4 target genes but this effect is only seen 
after a BMP4 alone maximal induction. This perhaps works through SU5402’s 
ability to inhibit the destabilizing phosphorylations on SMAD5 by FGF signaling.  
 




Figure 3.15 Enhanced expression of BMP4 target genes by SU5402.  
Taqman real time PCR analysis of selected BMP4 target genes. Fold change is expressed 
relative to undifferentiated hESC and expression was normalized to ACTB as an endogenous 
control. of the gene expression level of BMP4, SU5402, BS, B→BS and S→BS treated H1 
hESC compared to control untreated H1 hESC respectively. Ct values of untreated control 
H1 hESC are indicated. H1 hESCs were treated with BMP4, SU5402, combined 
BMP4+SU5402 (BS) treatment for the entire 16h or first for 6h with BMP4 followed by BS 
(B→BS) or SU5402 followed by BS (S→BS). 
 
3.5.4 BMP4-independent role of FGF 
Both from the NOGGIN experiments and the global gene expression profiling 
experiments from early time points of differentiation it was clear that SU5402 had at 
least some BMP4-independent roles in hESC induction towards the trophoblast 
lineage. Identifying the direct targets of FGF signaling that are independent of BMP4 
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may thus provide insight into the mechanism of SU5402-induced differentiation as 
well as potentially identifying downstream effectors of FGF signaling important in 
maintaining the pluripotent state. To identify such a list I focused on the 
SU5402+BMP4 and BMP4 alone v2 bead array data with its more current content.  
My list of FGF responsive genes independent of BMP4 signaling was generated by 
first identifying the genes down-regulated more than 3-fold after 8 hours 
BMP4+SU5402 treatment. This list was then reduced by only keeping genes in this 
list that were not also down-regulated more than 2-fold after 8 hours of BMP4 
treatment. Finally this list of 89 genes was further reduced to the 39 genes in Figure 
3.16 by removing any genes that did not remain down-regulated more than 3-folds 
after 48 hours treatment with BMP4+SU5402. This last filter was done on the 
assumption that genes involved in the maintenance of pluripotency would remain 
repressed throughout the initial stages of differentiation. 
Within this final list (Figure 3.16) there are some very interesting targets that provide 
a rich source of genes for future functional studies. Both ETV1 and ETV5 are Ets 
class transcription factors known to be FGF downstream targets (Brent and Tabin, 
2004; Firnberg and Neubuser, 2002; Tsang and Dawid, 2004) though no role in 
hESC biology has been described for them. FOXD3 is necessary for maintaining the 
pluripotency of mESC (Hanna et al., 2002), ZIC2 and ZIC5 are paralogs of ZIC3 
which is required for maintaining pluripotency of both mESC and hESC (Lim et al., 
2007). A TGF-β receptor, TGFBR2 which is upstream of SMAD2/3, is in this list 
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suggesting a signaling mechanism through this receptor plays a role in maintaining 
hESC pluripotency. NR5A2 is known to regulate POU5F1 expression in mouse (Gu 
et al., 2005). Also included is a histone deacetylase inhibitor, HDAC9, suggesting a 
role for epigenetic regulation. Also included in the list is ELAVL2, an RNA binding 
protein which influences RNA editing, localization, stability and translation.  
 
Figure 3.16 Genes significantly down-regulated specifically in BMP4+SU5402 
treatment but not in BMP4 only treatment. The colour spectrum from dark red to dark 
blue respectively represents the relative up-regulation to down-regulation. 
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3.5.5 BS effect is not specific to the H1 hESC line 
Different human ES cell lines can be biased in their differentiation potential. To 
determine whether the BS treatment I have characterized on the H1 hESC line was 
not specific to this particular line but universal to human pluripotent ES cells I 
performed the same treatment on the HES2 hESC line from ESI, a line derived by a 
different group under different conditions than the H1 line(Reubinoff et al., 2000). 
Both the H1 and HES2 lines were treated in parallel starting at the 4th day after 
passage and the treated cells were harvested at the time points of 1, 2, 4, 8, 16, 24 
and 48 hours post-treatment. Although there were no obvious morphological changes 
between control and any of the treated cells up to 48 hours for either of the hESC 
(Figure 3.17) as the morphological changes only begin to occur by day 3 of 
treatment, the gene expression of trophoblast markers and pluripotent markers in 
HES2 responding to BS treatment are highly similar to H1 experiment. I had earlier 
treated the HES2 line for 6 days with the combined BS and had documented 
substantial morphological changes (data not shown) not unlike that seen for H1. 
As seen from the above early time point expression bead array data there are 
significant gene expression changes seen in early time points upon BS treatment so I 
next compared gene expression between the two hESC lines at these early time 
points by Taqman real time PCR (Figure 3.18). The mRNA expression patterns of 
both H1 and HES2 upon BS treatment were strikingly similar both in the 9 
trophoblast genes that were up-regulated and also in the down-regulation of NANOG. 
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Although in the HES2 line this NANOG down-regulation is not as great as in H1 it 
appears to continue to decline at the last time point. Again, all this Taqman data 
independently confirms the bead array data. Of the significantly up-regulated 
trophoblast markers, a number were rapidly and significantly up-regulated upon BS 
addition even within 1 hour (e.g. TFAP2A, MSX2, GATA2, GATA3, CDX2, HAND1 
and ID2) suggesting that these transcription factors are the mediators of the 
BMP4-induced trophoblast differentiation. Other transcription factors have a delayed 
response to the BS treatment (e.g. DLX3 up at 8 h) indicating an indirect response to 
BS induction. Of note is the expression pattern, although initially responding rapidly 
(within 1 h) it is subsequently down-regulated from 4 to 8 hours and then 
up-regulated again, suggesting multiple mechanisms in its transcriptional activation 
in the trophoblast lineage. In summary here, it is clear that the combined BS 
treatment is a powerful inducer of the trophoblast lineage in multiple hESC lines. 




Figure 3.17 Cell morphologies of H1 and HES2 hESC treated with BS for 2 days. 




Figure 3.18 BS treatments on both H1 and HES2 hESC. 
mRNA expression profiling. The x-axis shows the hours of treatment and the y-axis shows 
the difference between the Ct values of a specific time point compared to the average Ct 
value of all time points. The higher on the y-axis, the less Ct value is, meaning the earlier 
detection and so is the more mRNA expression. The blue lines are mRNA expression levels 
of H1 hESC, and the pink line is the mRNA expression levels of HES2 hESC. 
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3.6 Cell fate commitment time point of H1 hESC treated with BS 
The hESC differentiation induced by the combined treatment of BMP4+SU5402 is a 
rapid and uniform process. Within 1 hour of treatment, significant up-regulation of 
placental markers is detected. Morphological changes are consistently detected on 
the 3rd day of treatment. Morphologically the majority of the hESCs are 
differentiated by the 5th day of treatment. At some point in cellular differentiation 
processes a cell reaches a point of no return before which it can dedifferentiate back 
to the original cell and after which it cannot, that is to say a point of commitment. 
Thus I designed my next experiment to determine at which point the combined BS 
treatment results in commitment to the trophoblast lineage by hESC (Figure 3.19A). 
In this experiment hESC cultures were treated with BS for 4, 8, 16, 24, 48 and 72 h, 
respectively and then RNA was harvested either immediately or after the cells were 
allowed to ‘recover’ in hESC media without BS for 24 and 48 h. Thus for each time 
point of treatment, there were three samples. Taking the 16 hours treatment for 
example, the three samples are  “16 hours BS treated”, “16 hours BS treated+24 
hours recovery” and “16 hours BS treated+48 hours recovery”. These experiments 
were carried out in biological triplicate. All samples were analyzed by Taqman real 
time PCR for the expression of three pluripotency markers, 12 trophoblast markers, 
and ACTB as the endogenous control (Figure 3.19). 
With the dramatic and immediate up-regulation of many transcription factors known 
to be important players in driving the trophoblast transcriptome I initially expected 
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that the commitment time point would be relatively early hence the inclusion of the 4 
and 8 hours time points. Upon analysis of these early time points it was clear that 
cells had yet to commit. Although the early trophoblast markers were all activated in 
these two treatments upon the 24 and 48 hours recoveries these markers had all gone 
back to undifferentiated hESC levels and the pluripotency markers remained 
unchanged at undifferentiated hESC levels. Thus the initial activation of trophoblast 
transcription factors was not enough to commit cells down the trophoblast lineage. 
Looking at the gene expression data from the longest BS treatment period (72h) it is 
clear that the cells are committed (Figure 3.19B). All the trophoblast markers remain 
elevated after 48h of recovery. In addition, NANOG, which is virtually nil after 48h 
of BS treatment (both shown here and from the bead array time course experiments), 
remains repressed after 48h of recovery from 72h of treatment. OCT4 levels, which 
by 72h of BS treatment has yet to reach its fullest down-regulation, continues to fall 
over the recovery period from 72h treatment (Figure 3.19B). My conclusion here is 
that by 72h the hESC treated cells are committed to the trophoblast lineage.  
Focusing on these two pluripotency markers in the treatment times of 16 and 24h it 
is evident that neither the NANOG nor OCT4 levels fall either initially or within the 
48h recovery period. In the 16h treatment many of the trophoblast gene expression 
levels fall back down, from their initial activation, towards that of undifferentiated 
hESC levels during the 48h recovery, for instance CDX2 falls back fully to 
undifferentiated hESC levels by 48h of recovery (Figure 3.19B). Though many of 
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these trophoblast markers remain high during recovery in the 24h treatment, I would 
argue that these cells are not committed as the pluripotency markers remain 
abundantly expressed. Though I did not do the experiment, it would be interesting to 
see what comes of the elevated levels of the pluripotency and trophoblast markers 
after longer periods of recovery in hESC media, with the known dominance of the 
pluripotent cell seen from cell fusion experiments, I would predict that the 
trophoblast markers would fall and the eventual transcriptome revert to that of an 
undifferentiated hESC. 
The earliest length of BS treatment that appears to commit the cells to the 
trophoblast lineage is 48h. All trophoblast markers remain abundantly expressed in 
the recovery period and NANOG expression remains repressed (Figure 3.19B) but 
most notable is the behavior of OCT4. OCT4 levels after 48h of treatment have only 
begun to start to fall but during the recovery period OCT4 levels continue to fall. 
After 24h of recovery OCT4 levels are equivalent to that a cells treated continuously 
with BS and they continue to fall thereafter. Thus I conclude the point of trophoblast 
commitment of hESC cells is reached after 24h but prior to 48h of continuous BS 
treatment. 
The behavior of SOX2 in these experiments is interesting/unusual. Although the 
SOX2 probe on the bead array was problematic, here the Taqman probe is showing 
dramatic down-regulation but only after at least 72h of BS treatment and 24 to 48h 
of recovery (Figure 3.19B). In mouse, Sox2 is known not only to be essential in the 
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pluripotent cell but also expressed and essential to the trophoblast stem cell of the 
early placenta (Avilion et al., 2003). Thus the persistent expression of SOX2 
examined by Taqman Q-PCR here may reflect a trophoblast stem cell (aka. 
cytotrophoblast) stage that the cells are passing through and have subsequently 
passed through after the down-regulation of SOX2. This is intriguing and points 
toward the possibility of capturing different trophoblast cell types by altering the 
growth conditions and/or content of the media (see Future Work below). 
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3.7 Inhibition of FGF signaling in mESC 
FGF signaling is essential for maintaining hESC pluripotency, however it is not a 
requirement in mouse ES cell culture. As reviewed in the Introduction, in mouse 
early embryo development FGF signaling is required at multiple stages including 
blastocyst and primitive endoderm formation, and the maintenance and proliferation 
of trophoblast stem cells. As a comparison to the hESC system I was interested to 
see what effect FGFR inhibition (ie. SU5402) would have on mESC cultures. As LIF 
is essential for maintaining mESC pluripotency combinations of this and SU5402 
were used. 
3.7.1 Combination effect of LIF pathway activation and FGF receptor inhibition 
on mESCs 
Feeder-free E14 mESCs were cultured in four conditions: +LIF/-SU5402, 
-LIF/-SU5402, -LIF/+SU5402, and +LIF/+SU5402. The concentration of SU5402 
used the same as on hESC (20 µM). The presented data is of mESCs cultured in the 
presence of the treatments for 48h . 
3.7.1.1 Morphology of treated mESC 
The morphology of the treated mESC cultures with the combinations of LIF and 
SU5402 are shown in Figure 3.20. +LIF/-SU5402 mESC cultures are the control as 
this is the normal culture media, the colonies represent the undifferentiated 
morphology of feeder-free mESCs. This culture is a little over-grown as it is on the 
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third day post-splitting, in the routine culture of mESC in this media the cells would 
be split every other day. Compare this undifferentiated morphology to that of the 
mESC cultured with neither LIF nor SU5402, where the sharp edges of the colonies 
are no longer visible which indicates the first signs of differentiation. Interestingly, 
when I removed LIF but included the FGFR inhibitor (–LIF/+SU540) the colonies 
maintained an undifferentiated morphology with more defined edges than even the 
control though the cleaner edges may be related to the slower apparent growth of 
these cultures. mESC cultured with both +LIF/+SU5402 showed undifferentiated 
morphology very similar to the control and the apparent proliferation in these 
cultures was increased over the SU5402 only. Based on morphology alone it appear 
that SU5402 treatment alone was blocking differentiation, an entirely opposite effect 
to that seen on hESC cultures. 
 
Figure 3.20 The morphology of feeder-free mESC treated with the combinations of LIF 
and SU5402. 
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3.7.1.2 mRNA expression profiling of treated mESC  
As shown Figure 3.21, consistent with the morphological observation, the mRNA 
expression level of pluripotency markers Nanog and Sox2 were up-regulated by 
SU5402 treatment compared to the control regardless of whether LIF was present in 
the medium. The mESC cultured with both LIF+SU5402 showed the highest 
expression of pluripotency markers. The expression level of Nanog and Sox2 were 
down-regulated, as would be expected, when neither LIF nor SU5402 was present in 
the medium. The less sensitive pluripotency marker Pou5f1 did not significantly 
change. 
The expression of primitive endoderm markers Gata6 and Sox17 were most 
significantly down-regulated in the –LIF/+SU5402 cultures suggesting that FGF 
inhibition is blocking the formation of the primitive endoderm similar to that seen in 
the mouse embryo (Arman et al., 1998). 
 
Figure 3.21 The mRNA expression profiling of SU5402 treated mESC.  
The left panel shows the pluripotency markers NANOG, POU5F1 and SOX2 and the right 
panel shows the primitive endoderm markers GATA6 and SOX17. The Ct value shows the 
mRNA expression level in the untreated mESC which was set as the control. The Y-axis 
shows the fold changes compared to the control on log10 scale. 
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3.7.1.3 Protein expression of treated mESC detected by Western Blot 
To analyze whether the up-regulation in mRNA levels of Nanog detected upon 
SU5402 treatment of mESC also corresponded to an increase in protein levels I 
performed Western blots on feeder-free mESCs cultured for 2 days in +LIF only, 
-LIF/-SU5402, and –LIF/+SU5402. Indeed, the protein levels corresponded to that 
seen for mRNA levels, Nanog levels in mESCs cultured without either LIF or 
SU5402 showed the lowest levels whereas that without LIF but including SU5402 
gave a strong signal even greater than that in the control (Figure 3.22). 
Recent work by others has characterized the use of inhibitors to maintain the 
undifferentiated state of mESCs using this or similar inhibitors of FGF signaling 
similar to the effect I have seen (Kunath et al., 2007; Ying et al., 2008). There are 
striking contrasts in the effects of FGFR inhibition between human and mouse ES 
culture systems, one (human) leading to uniform trophoblast differentiation whereas 
the other (mouse) maintaining the undifferentiated state of ES cells. It remains 
unclear the underlying molecular mechanisms to these differences but it is certainly 
clear from my data that there is a striking contrast in the immediate response of 
NANOG to FGF signaling. Nanog expression responding to FGF signaling inhibition 
is up in the mouse system but down in the human system. 
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In this thesis, I have developed a new method for differentiating human ES cells 
uniformly down the trophoblast lineage. The study was initiated by focusing on a 
feature of hESCs that differed from mouse ES cells, namely the requirement for FGF 
signaling for the maintenance of the undifferentiated state. By initially probing this 
pathway by use of a specific inhibitor to FGF receptors I identified that blocking this 
pathway leads to the up-regulation of trophoblast markers similar to the previously 
defined response of hESC to BMP4 signaling. By combining the two, I discovered 
an extremely robust method of uniform differentiation to the trophoblast lineage. 
This model has great utility not only in understanding the development of the human 
placenta but as a general model of differentiation from a pluripotent/totipotent state.  
4.1 How does this model compare with others?  
As stated, BMP4 induction of hESC towards the trophoblast lineage had previously 
been described (Xu et al., 2002b) characterizing an apparently robust and rapid 
differentiation of the H1 (in addition to H7 and H9) hESC line. However, others 
using a different hESC line (HES2 and HES3) indicated a different outcome upon 
BMP4 treatment (Pera et al., 2004), directing these cells to that of extraembryonic 
(or primitive) endoderm. Using the H1 and HES2 lines here I show that the 
combined treatment of these with SU5402+BMP4 leads to both these cell lines 
differentiating towards the trophoblast lineage. 
When I treated H1 hESC with BMP4 alone I did see dramatic activation of 
trophoblast genes but, in contrast to the combined treatment, there lacked a robust 
   
 
136
down-regulation of pluripotency genes. One difference between my culture and Xu 
et al. (2002b) is that I maintained the levels of FGF2 in the media as per hESC media 
prep whereas Xu et al removed FGF2 from the media. I may have seen a more robust 
differentiation response if I had also removed FGF2 from the media. I would argue 
however, that it would not be as substantial as when SU5402 was included as hESCs 
themselves make FGF2 which would provide at least a base line of FGF signal 
activation. 
Other methods have also been used to derive trophoblast cell types from hESC 
cultures. These include spontaneous differentiation methods by way of EB formation 
(Gerami-Naini et al., 2004; Harun et al., 2006) and by genetically manipulating 
hESCs by the knockdown of POU5F1/OCT4 (Babaie et al., 2006). Both methods are 
less advantageous than the method I have developed as neither is as uniform and 
genetic manipulation moves the cells further from the in vivo cell type. Thus the 
method described in this thesis is the best method to date for the differentiation of 
hESC to the trophoblast lineage providing robust activation of trophoblast makers 
and down-regulation of pluripotency markers within hours of treatment and full 
commitment to the trophoblast lineage within 48 hours of treatment. 
4.2 Mechanism of trophoblast induction by BMP4 and SU5402 
The mechanism of action of BMP4 has been well characterized in other cellular 
systems. It is known to signal through its integral membrane receptors to 
phosphorylate and activate cytoplasmically localized SMAD1/5/8. Upon activation 
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the SMAD moves to the nucleus and activates target genes. Using an antibody 
recognizing the activated form of all three of these BMP SMADs I identified an 
enrichment of nuclear-localized staining of this shortly after the addition of BMP4 to 
the hESC media. Based on the gene expression bead array studies it appears that the 
predominant BMP SMAD present in hESC cells is SMAD5. Thus the initial step in 
trophoblast induction by BMP4 is through the activation and nuclear localization of 
SMAD5.  
Having generated comprehensive global gene expression data sets including from 
the earliest time points of 1 and 2 hours post-induction I could identify the genes that 
were immediately responsive to BMP signaling. From the BMP4 alone time series 
there are 139 genes up-regulated greater than 2-fold within 2 hours and 28 greater 
than 4-fold. TFAP2A, GATA2, HAND1, MSX2, ID2, CDX2, and GATA3, all 
well-known trophoblast regulators, are up-regulated at least 7-fold within 2 hours of 
BMP4 induction and are among the top 11 up-regulated genes at this time. Just any 
one of these, when over-expressed in mouse ES cells, is capable of driving the 
trophoblast transcriptional program (Niwa et al., 2005) so it stands to reason that 
these seven provide a comprehensive activation of the trophoblast transcriptional 
program. 
Whether they are direct targets of SMAD5 remains to be determined though the 
evidence is strong that they are. MSX2, GATA2, GATA3, and ID2 have all been 
identified previously as responsive to SMAD signaling and contain a combination of 
BMP-responsive element (BRE, TGGCGCC) and Smad binding element (SBE, 
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GTCT) (Karaulanov et al., 2004). This combinatorial element is significantly 
enriched in my 139 gene list of early (2h) responders and is also specifically found 
in CDX2 (Mikael Huss, GIS). Though I do not provide the ultimate proof of direct 
interaction (ChIP) it is clear that many trophoblast transcription factors are 
immediately responsive to BMP4 signaling and that this is likely the primary reason 
BMP4 directs hESC to the trophoblast lineage.   
Though at 3 days after induction both SU5402 and BMP4 independently treated 
hESC cultures have a very similar transcriptional response with major up-regulation 
of the trophoblast transcriptional program, analysis of early time points (2 and 8h) 
indicate SU5402 does not directly activate trophoblast transcription factors. The 
activation of these appears to be later at the 8 to 16h transition. This up-regulation is 
likely a result of stabilization of SMAD5 by inhibiting an FGF-mediated 
destabilizing phosphorylation (Sapkota et al., 2007) that enables a greater threshold 
of activation of trophoblast transcription factors over and above that seen with 
BMP4 alone.  
This synergy between SU5402 and BMP4 is not the sole role of FGFR inhibition as 
there are notable early gene expression changes mediated by SU5402 (as highlighted 
in Figure 3.16). There are at least two pluripotency transcription factors (FOXD3 
downregulated to 8% and NR5A2, downregulated to 9%) in this list of early 
down-regulated genes that are known to regulate POU5F1/OCT4, the assumption 
than is that FGF signaling in undifferentiated hESC cultures indirectly regulate 
OCT4 through these factors and by inhibiting this signaling OCT4 is down-regulated. 
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Other genes in this list include integral membrane receptors, histone deacetylase 
inhibitors, and RNA splicing factors suggesting complex roles for FGF signaling in 
the maintenance of hESC.  
4.3 Regulatory Networks in Human Placental Development 
Much work has been done in cell lines derived from the placenta to identify 
transcription factors regulating important molecules in placental physiology such as 
in hormone production. With my model of trophoblast differentiation I can begin to 
discern the developmental progression of the regulatory networks that eventually 
activate the placental-specific gene expression program. In Figure 4.1 (regulatory 
network) and 4.2 (developmental expression profiles) I begin to construct some of 
these networks based on previously characterized gene interactions and my temporal 
gene expression profiles.  
BMP4 signaling, via activation of SMAD5, mediates the initial up-regulation of 
MSX1/2, ID1/2, GATA2/3, CDX2, and DLX3/5. GATA2/3 (Steger et al., 1994) and 
DLX3 (Roberson et al., 2001) are all known to directly activate the gene encoding 
the α subunit of hCG (the pregnancy hormone), CGA. The promoter region of CGB5, 
one major form of hCG subunit CGB, was shown to interact with PPARG through 
PPARG and RXRA dimerization (Tarrade et al., 2001). PPARG is activated by 40h 
of BS induction and RXRA is expressed at a steady state throughout. In addition, the 
induction of both CGA and CGB was shown to require TFAP2C (LiCalsi et al., 2000; 
Steger et al., 1993). Because both α and β-subunits of hCG are inhibited by POU5F1 
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(Liu et al., 1997; Liu and Roberts, 1996), these two genes were actually the first 
identified human targets of POU5F1/OCT4. CGA (activated by 3 days) and CGB 
(activated from 3 to 7 days) are not activated until the down-regulation of POU5F1. 
GCM1, activated from 72 to 96h in my differentiation system, is another 
trophoblast-specific transcription factor known to regulate placental hormones. The 
initial activation of GCM1 may be mediated by GATA2/3 as several potential 
GATA binding sites have been identified in its promoter (Yamada et al., 2000). 
Subsequently, GCM1 can activate its downstream targets PGF (Chang et al., 2008), 
ERVWE (encoding syncytin; (Yu et al., 2002a)) and CYP19A1 (Nait-Oumesmar et 
al., 2000; Yamada et al., 1999). CYP19A1 encodes aromatase, which catalyzes the 
last steps of estrogen biosynthesis (Nait-Oumesmar et al., 2000; Yamada et al., 
1999) and like 17βHSD type 1 which catalyzes estrone (one form of estrogen) to 
estradiol, is up-regulated in the later stages of the differentiation program. 
Estradiol-17β has a well-described function in trophoblast development (Takeyama 
et al., 1998).  
Other placental hormones can be integrated into this nascent network. TFAP2 family 
members are known to bind the promoters of CSH1 (Richardson et al., 2000) and 
GH1 (Courtois et al., 1990; Imagawa et al., 1987). Considering the high sequence 
conservation between GH1 and GH2, and between CSH1 and CSH2, TFAP2A/C 
may also bind to and activate GH2 and CSH2. TEAD3 is also known to bind to 
CSH2 (Jacquemin et al., 1997; Jacquemin et al., 1998). CSH1, CSH2 and CSHL1 are 
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all up-regulated after the BS treatment. Placental lactogen (PL) may signal, with 
GH2, to the mother to stimulate IGF1, enhancing the availability of glucose and 
amino acids to the fetus (Caufriez et al., 1994; Handwerger and Freemark, 2000; 
Whittaker et al., 1990). IGFBP binds to IGF to sustain the IGFs and alters their 
interaction with cell surface receptors. The promoter of IGFBP1 was found to be 
activated by relaxin (Tang et al., 2005). Since there is virtually no expression of 
IGF1 or IGFBP1 but a huge up-regulation of IGF2 and IGFBP3 in H1 hESC treated 
with BS, it is likely these later genes play a critical role in this signaling (Figure 4.1 
and Figure 4.2).  
 
 
Figure 4.1 Regulatory network responding to BS treatment in hESC  
(A) The possible regulatory network responding to BS treatment in hESC based on the 
known interaction and mRNA expression profiling of the genes. Orange color indicates the 
gene is up-regulated, green color indicates the gene is down-regulated and blue color 
indicates the FGF signaling related molecules. 












Figure 4.2 Developmental expression profiles of the genes in the regulatory network 
responding to BS treatment in hESC 
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4.4 Totipotency of Human ES Cells? 
The term totipotency refers to a cell that can give rise to all cell types of an organism, 
for instance the early blastomeres up until the 16-cell stage of mouse preimplantation 
development. These cells have yet to commit to any particular lineage as indicated 
by classic fate mapping studies thus, as these cells can contribute to all cells both 
extraembryonic and embryonic, they are considered totipotent. In contrast, mouse ES 
cells are considered as only pluripotent as, although they can contribute to all cells of 
the embryo proper, they do not contribute to the trophoblast lineage. 
From the first description of human ES cells (Thomson et al., 1998) it was clear that 
these cells could at least give rise to some trophoblast cell types. Does this mean that 
hESCs are representative of an earlier developmental position than that of their 
mouse counterparts? This remains a debatable topic. The ability of mouse epiblast 
stem cells to give rise to trophoblast cells (Brons et al., 2007), or at least cells 
expressing markers of trophoblast, complicates matters. However, the ongoing 
debate is mainly because so little is known of the developmental potential of cells 
from the early human embryo. Both mouse and human ES cells are derived from the 
ICM of the blastocyst and it is often assumed (with no supportive evidence) that the 
developmental potential of the human ICM is the same as the mouse ICM (i.e. it 
does not contribute to the trophoblast). Perhaps the human ICM readily gives rise to 
the trophoblast lineage. 
Part of the reason I pursued the FGF signaling pathway for my investigations was to 
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try and address this debatable developmental position of hESCs as in the mouse this 
signaling pathway is required at multiple stages of early development including for 
the transition from the totipotent blastomere to the formation of the blastocyst (Chai 
et al., 1998). That said, it is hard to interpret my data on human ES cells in the 
context of what is known of FGF signaling in early mouse development, and the 
striking contrast I have shown for the response of mouse and human ES cells to 
SU5402 suggests there are substantial differences due to species variation. 
Nonetheless, my differentiation method points towards the robust ability of human 
ES cells to give rise to the trophoblast lineage. I would argue that it gives rise to the 
earliest trophoblast cell type, that of the trophectoderm within the blastocyst. This is 
based on the extensive similarity in transcription factor expression at the earliest 
time points of BS-induced hESC differentiation to that of transcription factors in the 
mouse trophectoderm (note there are no good expression data from human blastocyst 
or trophectoderm). In work that has been submitted for publication by the Robson 
lab many trophectoderm-specific transcription factors were identified by screening 
through over 800 transcription factors. Transcription factors expressed both in muse 
trophectoderm and human-derived early trophoblast include but are not limited to 
CDX2, GATA3, TFAP2A, TFAP2C, GATA2, CEBPA, and GRHL factors. In addition 
to these similarities, one of the most significantly up-regulated genes upon 
BS-induced hESC differentiation is fibronectin (FN1), this gene is known to be 
expressed specifically in the trophectoderm of the human blastocyst and has been 
suggested to play a role in embryo attachment to the uterine wall (Shimomura et al., 
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2006). Although still speculative in all, this is good suggestive evidence that hESCs 



























































In my thesis I have established the best model to date of human trophoblast 
differentiation from human ES cells. This robust & uniform differentiation of hESC 
along the trophoblast lineage is induced by the combinatorial treatment of human ES 
cells with a FGFR inhibitor and BMP4. When FGF signaling pathway in hESCs was 
inhibited or hESCs were treated with BMP4, the hESC lost the ability to remain in 
an undifferentiated state and differentiated rapidly towards the trophoblast lineage. 
When hESCs were treated with the combination of FGFR inhibitor and BMP4, the 
differentiation process towards the trophoblast lineage was much accelerated. The 
synergistic effect of FGF pathway inhibition and BMP4 activation in hESCs can be 
explained by crosstalk between the two pathways. BMP4 activates the downstream 
target SMAD1 by phosphorylating its C-terminus. The C-terminal-phosphorylated 
SMAD1 translocates from cytoplasm to nucleus and there functions as a 
transcription factor. The activation of the FGF pathway phosphorylates Erk in the 
downstream MAPK pathway. Activated Erk phosphorylates MAPK sites in the 
linker region of SMAD1 enabling SMAD1 polyubiquitination by ubiquitin ligase 
SMURF1. The ubiquitination of SMAD1 leads to its degradation thus suppressing 
the effect of BMP4 signaling. Therefore, when hESC cells are treated with the FGFR 
inhibitor, at least part of its effect is a block in this negative phosphorylation of the 
SMAD1 linker region and subsequent degradation. Endogenous BMP4 present in the 
system is thus more effective in inducing trophoblast gene expression. I do also 
show that there is a BMP4-indpendent effect of SU5402 treatment that leads to 
doen-regulation of some key pluripotency factors. 
This model is ideal for investigations into the molecular regulation of the 
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trophoblast/placental lineage. It can be utilized for investigations into the dynamic 
process of hESC differentiation process rather than static observation. What is more, 
this model provides an in vitro way to understand the molecular regulation of 
implantation & placentation and also ideal for studying the human genome’s 
transition from a totipotent to a committed state. As such I anticipate its wide use in 
the future.  
5.2 Future work 
This work has already spawned a number of projects in the Robson lab, future works 
include 1) investigations into the molecular functions in maintaining pluripotency of 
the FGF responsive gene identified in this thesis; 2) modeling human embryo 
implantation; 3) human developmental functional genomics studies using small 
interfering RNA (SiRNA); and 4) deriving specific trophoblast cell types (such as 
the cytotrophoblast) by altering the length of induction and playing with the growth 
conditions/media components. 
It is a particular challenge to validate these in vitro human trophoblast cells that I 
have generated as there is no appropriate in vivo model of early human trophoblast 
lineage. Indeed, extremely little to no molecular characterization of these early in 
vivo trophoblast cell types have taken place due to inaccessibility of the tissue. A key 
area of future work is to attempt to derive, by altering growth conditions, different 
trophoblast cell types, with the initial step of differentiation from hESC using the 
method I have characterized in my thesis. Perhaps 3-dimensional culture systems 
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that include the cells types found in the receptive human endometrium will 
ultimately prove successful in understanding these earliest of cell types so essential 
to human embryonic development. Finally, though some insight may be gained by 
studying other primate systems, it is essential to use human cells to fully undestand 
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